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Among modified-release oral dosage forms, increasing interest has currently 
been addressed to delayed/pulsatile delivery systems [Maroni A. et al., 2013b; 
Maroni A. et al., 2005]. They are intended for the liberation of the conveyed 
active ingredient after a programmed time period (lag phase) that starts with the 
administration of the dosage form. Such a strategy meets the principles of 
chronopharmacology, which is based on the knowledge that both the 
symptomathology of a large number of pathologies and the pharmacokinetics 
and pharmacodynamics of a variety of drugs are influenced by biological 
circadian rhythms. The possibility for oral pulsatile delivery systems of finding 
application in chronotherapy is interesting for those diseases whose symptoms 
occur mainly during the night or in the early morning, such as bronchial asthma, 
angina pectoris, rheumatoid arthritis. Indeed, the administration of the drug 
delivery system (DDS) at bedtime increases patient compliance, since it may 
circumvent the need for waking up for drug intake; furthermore, the drug 
liberation in conjunction with the onset of symptoms allows to decrease the 
dose and/or avoid the useless and potentially dangerous exposition of the 
patient to the drug in the early hours of sleep, when it wouldn’t be necessary 
[Youan B-B.C., 2004].  
Delayed/pulsatile orally-administered systems may also be exploited to achieve 
site-specific delivery of drugs in the colonic region, based on a time-dependent 
approach [Maroni A. et al., 2013a; Gazzaniga A. et al., 2006]: a device ensuring a 
lag time prior to release could target specific regions of the gastrointestinal tract 
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on the basis of experimental data indicating that the transit time through the 
small intestine is relatively constant (3 h ± 1 standard error) and independent of 
the type of dosage form. Indeed, by the application of a gastroresistant (GR) 
outer film, which allows to overcome gastric emptying variability, the first 
contact with biological fluids is shifted soon after the dosage form is emptied 
from the stomach; then, by imparting a lag phase that matches the small 
intestine transit time (SITT), the drug liberation can occur in the target region. 
Great interest is focused on colon-specific release for the local treatment of 
inflammatory bowel disease (IBD), such as Crohn’s desease and ulcerative 
colites, and infective, tumoral as well as neurovegetative colonic pathologies. 
Moreover, this strategy can also find application in the improvement of the oral 
bioavailability of peptides and proteins. Although the colon is not considered as 
an advantageous site for absorption because of its anatomic and physiological 
characteristics, the long residence time and the lower concentration of local 
peptidases were proven to partially offset its unfavourable characteristics. 
Several strategies for achieving delayed/pulsatile release following oral 
administration were proposed, generally leading to capsular, osmotic or 
reservoir systems [Maroni A. et al., 2013b; Gazzaniga A. et al., 2008; Bussemer T. 
et al., 2001]. Capsular systems have been designed having an insoluble body 
filled with a drug preparation. The shell body is sealed with a swellable, erodible 
or lipophilic matrix plug, which is removed upon swelling and/or erosion, both 
promoted by the contact with water, or as a consequence of a pressure rise 
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created inside the capsule by water uptake. Osmotic devices are formed by the 
drug formulation core including an osmotic and, in some cases, a semi-
permeable membrane. Such membrane is provided with a calibrated orifice, 
from which the drug is pumped out at a constant rate; drug release starts after a 
silent phase, coinciding with the time required for water penetration into the 
core of the osmotic pump. Lastly, reservoir systems are also available: they 
consist of a drug-containing core, which could be either a single- or multiple-unit 
one, covered by at least one coating layer. On the basis of the composition of 
such layer, these systems can be distinguished in erodible, rupturable or 
diffusive. In particular, erodible devices show the ability to impart a lag phase 
before release, following the dissolution/erosion of a polymeric barrier 
separating the drug-containing core and the aqueous environment. The lag 
phase can be modulated by the characteristics of the polymer and the thickness 
of the coating. Hyroxypropyl methylcellulose (HPMC), hydroxyethylcellulose 
(HEC) and hydroxypropylcellulose (HPC) are the most commonly employed 
polymers.  
The research group where I carried out my PhD project had already developed an 
oral DDS for delayed and site-specific release of drugs in the form of an erodible 
reservoir system, named Chronotopic™ [Cerea M. et al., 2008; Zema L. et al., 
2007; Sangalli M.E. et al., 2004; Sangalli M.E. et al., 2001; Gazzaniga A. et al., 
1995; Gazzaniga A. et al., 1994a; Gazzaniga A. et al., 1994b ; Maffione G. et al., 
1993]. It is based on a functional coating composed of a hydrophilic polymer 
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(generally HPMC) applied by different techniques (press-coating, spray-coating 
and powder-layering) onto several types of cores (tablets, capsules, pellets). This 
layer of few hundreds microns of thickness delays the contact of the biological 
fluids with the drug-containing core through hydration, swelling and 
dissolution/erosion phenomena, as outlined in Figure 1. The effectiveness of the 
Chronotopic™ system, its flexibility in terms of duration of the lag phase, both in 
vitro and in vivo, as well as the possibility of scaling up the manufacturing 
process have been demonstrated. 
 
 
Figure 1: Scheme of the interaction and release performance of a Chronotopic™ 
system with aqueous fluids. 
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On the basis of the encouraging results obtained, the possibility of exploiting 
hydrophilic polymers for the development of a functional container with the 
same ability of delaying drug release was investigated [Gazzaniga A. et al., 2011a; 
Gazzaniga A. et al., 2011b]. Such a device was conceived in the form of a capsular 
shell conveying a variety of drug formulations (solid, semisolid, liquid) filled by 
means of conventional equipment already available on the market. Notably, such 
a device would reduce the technical and regulatory burden associated with 
development and, thus, the relevant costs with respect to coated systems. In an 
early phase, the use of the hot melt extrusion (HME) technique to prepare the 
container was explored: it requires that raw materials have a thermoplastic 
behavior, which is the property of undergoing a transition to a viscous state upon 
heating [Foppoli A. et al., 2009]. HPMC, however, exhibited the desired plastic 
behavior only when worked at temperatures at which its thermal degradation 
occurs, even in the presence of plasticizers. Hence, another hydrophilic 
derivative of cellulose, HPC, was considered for the preparation of functional 
containers, since it shows thermoplastic properties and the same behavior of 
HPMC when in contact with aqueous fluids. Moreover, HPC is available on the 
market in several viscosity grades, suggesting the possibility of achieving a high 
flexibility in the performance of the delivery platform. The plasticized polymer 
was extruded into films, which were then press-molded into semi-spherical 
halves of shells, filled with a drug tracer, paired and sealed to form two-piece 
spherical capsules. Preliminary data from such devices demonstrated their ability 
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to delay the release of the contents as a function of the composition. However, 
the manufacturing technique involved a number of limitations especially with 
regard to the industrial scalability.  
In view of these premises, a different approach was preferred based on the 
application of the injection molding (IM) technique that gives several 
advantages, such as the possibility of an easy scale-up, versatility and prospects 
of patentability. Indeed, although IM has been widely exploited in the plastic 
field, only few pharmaceutical applications have been reported [Zema L. et al., 
2012; Vilivalam V.D. et al., 2000; Rothen-Weinhold A. et al., 1999; Stepto R.F.T. 
and Tomka I., 1987]. IM can be defined as the forced injection of heated 
thermoplastic polymers into a 3D mold to be shaped while cooling and 
hardening. The IM equipment employed for the manufacturing of capsular 
devices was a bench-top press, particularly indicated for the production of small 
items with high precision (micromolding press). Raw materials, loaded in a 
hopper, are conveyed by means of a piston into a heated-controlled plastication 
block, where they undergo softening and mixing; then, the molten mass is 
forcedly injected through a nozzle into the mold. This consists of two units, one 
mobile and the other mounted on a fixed platen: once the two halves are 
combined, the cavity image of the item to be molded is formed. When injected 
into the mold in the closed configuration, the molten material spreads into the 
cavity and assumes the desired shape, which can be maintained thanks to the 
solidification promoted by cooling. Finally, the molded product is ejected. Figure 
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2 shows an outline of a general IM cycle, which combines two synchronized 
phases: one comprises filling/opening/closing steps of the mold, while the other 
refers to the movement of the injection tool (generally a screw) moving forward 
to the injection position and being pushed back to the pre-injection one. After 
the automatic ejection of the molded product, a new IM cycle can start, allowing 
a continuous manufacturing process to take place. 
 
 
 
Figure 2: IM cycle in screw-type machine [adapted from Zema L. et al., 2012].  
 
With respect to the mold used for preparing capsular devices, given the need for 
carrying out early formulation studies, a highly versatile prototype mold that 
could also be exploited for improving skills in such new technique was designed: 
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indeed, it could guarantee high flexibility with respect to ongoing adjustments of 
both the formulation and the thickness of shells. Moreover, the mold was 
designed able to fulfill a number of requirements for the final device: i) the 
capsular system needed to have a size suitable for oral administration and to 
consist of matching body and cap items; ii) the shape and mechanical 
characteristics of the device were expected to be suitable for established filling 
procedures; iii) once assembled, the device was expected not to allow for leaks 
and to preferably have a plane external surface. The prototype mold was 
provided with a two-cavity set filled simultaneously for the production of cap 
and body within a single manufacturing cycle; moreover, it bore three couples of 
cavities to be selected prior to assembling (preselection of the differing 
thicknesses) (Figure 3). 
 
a)   b)  
Figure 3: Prototype mold for the preparation of cap and body items with 
differing thicknesses (a); detail of the injection orifice and adaptable 
pouring gate (b) [adapted from Gazzaniga A. et al., 2011a]. 
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A locking mechanism based on the mutual pressure of the contact areas of 
matching caps and bodies was studied, not entailing any junction gap and less 
complicated than that of regular gelatin and HPMC capsules (Figure 4). On the 
basis of previous studies on hydrophilic cellulose ethers used as delaying agents, 
nominal thicknesses of 300, 600 and 900 µm were hypothesized for capsules, in 
order to provide lag times of different duration. Because of the shape of the 
device, such values applied to the thinner wall areas, i.e. those where cap and 
body are not overlapped because of the locking system. Moreover, capsules 
were designed having the same external dimensions but decreasing inner 
volume, because of the increase in the wall thickness. 
     
Figure 4: Lengthwise representation of prototype capsules of 300 (a), 600 (b) and 
900 (c) µm thickness; areas colored in red are those which nominal 
thickness refers to. 
 
By the adjustment of process parameters, capsules of the selected shell 
thicknesses made of Klucel® LF with the addition of 10 w/w of polyethylenglycol 
(PEG) 1500 as the plasticizer could be obtained (Chronocap™) (Figure 5). 
a) b) c) 
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a)             b)  
 
Figure 5: Assembled capsule (a) and capsule bodies of 300, 600 and 900 µm shell 
thickness (b). 
 
Capsular devices with shell thickness of 300, 600 and 900 µm  based on Klucel® LF 
exhibited satisfactory technological characteristics as well as release 
performance (Table 1): reproducible in vitro lag phases (calculated as the time to 
10% release, t10%), increasing as a function of the wall thickness, were obtained. 
A prompt and complete release of the drug, promoted by the breakage and rapid 
dissolution/erosion of capsule shells, was observed both under static and 
hydrodynamic conditions (Figure 6). 
 
Table 1: Characteristics of Chronocap™ devices with differing shell thicknesses. 
 
nominal thickness thickness elastic modulus t10% in vitro 
µm µm (CV) N/mm
2
 (CV) min (CV) 
300 346 (12.30) 2.672 (15.04) 29.3 (22.2) 
600 645 (13.20) 5.342 (15.72) 53.5 (10.6) 
900 880 (4.64) 8.451 (3.44) 91.7 (3.16) 
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a)       b)  
 
Figure 6: Photographs at successive time points showing the opening of a 600 
µm thick Chronocap™ capsule immersed in deionized water under 
static conditions (a); mean release profiles of Chronocap™ capsules 
with differing shell thicknesses (b) [adapted from Gazzaniga A. et al., 
2011a]. 
 
The in vivo release performance of Klucel® LF devices was preliminarily evaluated 
on healthy volunteers [Zema L. et al., 2013; Gazzaniga A. et al., 2011c]. The 
appearance of drug in saliva samples was delayed with respect to the time of 
intake as a function of the shell thickness of capsular devices. After the lag phase, 
the drug concentration showed a fast increase in all cases (Figure 7; Table 2). 
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Figure 7: Average acetaminophen saliva concentration vs time profiles after oral 
administration of capsular devices with differing shell thicknesses 
[adapted from Gazzaniga A. et al., 2011c]. 
 
Table 2: Pharmacokinetics parameters after oral administration of capsular 
devices with differing shell thicknesses (standard deviation in brackets) 
[adapted from Gazzaniga A. et al., 2011c]. 
 
nominal shell thickness  tlag  Cmax  tmax  AUC0-24 
(µm) (h) (µg/ml) (h) (µg*h/ml) 
300 1.25 (0.17) 1.70 (0.46) 1.17 (0.29) 7.43 (3.25) 
600 2.34 (0.38) 5.07 (0.97) 2.50 (0.50) 16.06 (4.55) 
900 3.53 (0.71) 4.60 (0.97) 3.33 (0.58) 12.62 (0.28) 
 
Based on these premises, the aim of the present work was the further 
development of the Chronocap™ platform in order to improve its robustness and 
versatility, as well as to enhance the industrial scalability of the relevant 
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manufacturing process. In particular, the PhD project focused on: i) the 
development of a dedicated mold for the preparation of HPC-based capsules 
[Results - Chapter 1]; ii) the use of HPC molded capsules as substrates for coating 
processes in view of the development of a colonic delivery system based on a 
time-dependent approach [Results - Chapter 2]*; iii) the modulation of the lag 
phase of capsules through formulation changes [Results - Chapter 3]. 
Most of the results obtained from this research activity have been 
published/submitted for publication, in the form of experimental articles or 
poster communications: 
 
E. Macchi, L. Zema, A. Maroni, A. Gazzaniga, L.A. Felton. 2014. Enteric-Coating of 
Pulsatile-Release Capsules Prepared by Injection Molding, submitted for 
pubblication. 
L. Zema, G. Loreti, E. Macchi, A. Foppoli, A. Maroni, A. Gazzaniga. 2013. Injection-
Molded Capsular Device for Oral Pulsatile Release: Development of a Novel 
Mold, J Pharm Sci 102, 489-499. 
L. Zema, G. Loreti, A. Melocchi, F. Casati, E. Macchi, A. Gazzaniga, Oral delivery 
platforms in the form of “functional containers” prepared by injection molding. 
Thematic workshop of CRS Italian Chapter on "Design and industrial 
development of advanced drug delivery systems", Pavia, Italy, November, 2013. 
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E. Macchi, L. Zema, A. Gazzaniga, L.A. Felton, Enteric-coating of pulsatile-release 
capsules prepared by Injection Molding, AAPS Annual Meeting & Exposition, San 
Antonio, TX, November, 2013. 
E. Macchi, L. Zema, A. Gazzaniga, L.A. Felton, Enteric-coating of HPC capsules 
prepared by Injection-Molding, ACCP Annual Meeting, Albuquerque, NM, 
October, 2013. 
E. Macchi, L. Zema, A. Gazzaniga, L.A. Felton, Gastroresistant coating of HPC 
capsules prepared by Injection-Molding, 40th CRS Annual Meeting & Exposition, 
Honolulu, HI, July, 2013. 
E. Macchi, L. Zema, A. Gazzaniga, L.A. Felton, Release performance of Injection-
Molded HPC-based capsules filled with different formulations of a model drug, 
AAPS Annual Meeting & Exposition, Chicago, IL, October, 2012. 
L. Zema, E. Macchi, G. Loreti, A. Foppoli, A. Gazzaniga, Development of an IM 
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Injection-Molded Capsular Device for Oral Pulsatile Release: 
Development of a Novel Mold 
 
 
The content of this chapter has already been published in: 
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Abstract 
The development of a purposely-devised mold and a newly set up injection 
molding (IM) manufacturing process was undertaken in order to prepare 
swellable/erodible hydroxypropyl cellulose (HPC)-based capsular containers. 
When orally administered, such devices would be intended to achieve pulsatile 
and/or colonic time-dependent delivery of drugs. An in-depth evaluation of 
thermal, rheological and mechanical characteristics of melt formulations/molded 
items made of the selected polymer (Klucel® LF) with increasing amounts of 
plasticizer (PEG 1500, 5-15 % by weight) was preliminarily carried out. On the 
basis of the results obtained, a new mold was designed that allowed, through an 
automatic manufacturing cycle of 5 s duration, matching cap and body items to 
be prepared. These were subsequently filled and coupled to give a closed device 
of constant 600 µm thickness. As compared with previous IM systems having the 
same composition, such capsules showed improved closure mechanism, 
technological properties, especially in terms of reproducibility of the shell 
thickness, and release performance. Moreover, the ability of the capsular 
container to impart a constant lag phase before the liberation of the contents 
was demonstrated irrespective of the conveyed formulation. 
 
Keywords: Injection molding (IM); capsular device; microcompounder; pulsatile 
release; colon delivery; hydroxypropyl cellulose (HPC). 
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1. Introduction 
Injection Molding (IM) was recently explored as a manufacturing technique for 
the preparation of pharmaceutical dosage forms because of the several 
advantages it may offer with respect to production costs and 
technological/biopharmaceutical characteristics of the molded items [Zema L. et 
al., 2012]. In particular, molded capsular shells with different shape, design and 
composition were prepared, potentially suitable for a variety of filling 
formulations (e.g. powders, granules/pellets, semi-solid or liquid preparations). 
IM capsules made of starch or gelatin may represent an alternative to dip-
molded commercially-available ones for the formulation of immediate-release 
oral dosage forms, the administration of pellets or the production of coated 
modified-release dosage forms [Eith L. et al., 1986; Vilivalam V.D. et al., 2000; 
Watts P. et al., 2005]. However, innovative devices intended as a viable approach 
to new Drug Delivery Systems (DDSs) were also proposed. In this respect, the 
feasibility of capsular containers based on functional polymers (i.e. polymers 
with pH-dependent solubility such as hydroxypropyl methylcellulose acetate 
succinate, or matrix-forming agents) was demonstrated, and gastroresistant as 
well as pulsatile delivery systems were so far obtained [Gazzaniga A. et al., 
2011a; Gazzaniga A. et al., 2011b; Zema L. et al., 2013]. 
Swellable hydrophilic cellulose derivatives were successfully employed as release 
delaying barriers or coating agents in the development of an oral erodible 
delivery platform (Chronotopic™) intended for pulsatile and/or colonic delivery 
Injection-molded capsular device for oral pulsatile release: 
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[Conte U. et al., 1989; Gazzaniga A. et al., 1994; Gazzaniga A. et al., 2008; Zema L. 
et al., 2007; Maroni A. et al., 2010]. A lag phase prior to drug release was indeed 
achieved that could be exploited to obtain a site-selective release to the ileo-
colonic region based on a time-dependent strategy [Sangalli M.E. et al., 2001; Del 
Curto M.D. et al., 2009; Maroni A. et al., 2009]. By the use of hydroxypropyl 
cellulose (HPC), which offered a good balance between release-controlling 
performance and IM processability, capsular devices (Chronocap™) having good 
technological and stability characteristics were subsequently prepared. Such 
DDSs showed the pursued in vitro and in vivo release patterns, with lag times 
increasing as a function of the wall thickness and HPC viscosity grade [Gazzaniga 
A. et al., 2011c]. With respect to coated formulations for pulsatile delivery, the 
peculiar advantage of Chronocap™ would consist in the possibility of undergoing 
an independent pharmaceutical development irrespective of its final contents 
and manufacturing process, which could bring about important repercussions in 
terms of patentability and industrial scale-up. 
The mold prototype employed was highly versatile, as convenient for early 
formulation studies. Indeed, it allowed the preparation of matching caps and 
bodies within a single manufacturing cycle as well as the selection of differing 
nominal shell thicknesses in the 300-900 µm range. However, some practical 
limitations were entailed by the particular joint mechanism of the capsules, in 
which the contact areas of bodies and caps overlapped inside the shell cavity 
thus also leading to a thicker wall region. Moreover, the variability in the shell 
Injection-molded capsular device for oral pulsatile release: 
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thickness and its poor consistency with the nominal value needed to be 
overcome. In the prospect of an industrial scale-up, the production rate and 
extent of automation of the manufacturing process also required to be 
improved. 
Based on the dimensional characteristics (i.e. length in the order of 10 mm vs. 
thickness of few hundreds of micrometers that is reduced in the proximity of 
certain details) and tolerances involved, the proposed capsule shell would fall 
within the definition of micromolded products [Heckele M. and Schomburg W.K., 
2004; Giboz J. et al., 2007; Koç M. and Özel T., 2011]. Microinjection molding 
(μIM) is not only a simple scale-down of classical IM because it entails 
introducing radical changes into the equipment, the mold construction and the 
raw materials to be used. In particular, the mold design, formulation 
development and setup of process parameters (e.g. mold temperature, injection 
speed and pressure, holding time and pressure) should be carried out 
concomitantly. The aim of the present work was therefore the design of a special 
mold, dedicated to the production of HPC capsules, and the subsequent 
development of a manufacturing process able to enhance the industrial 
scalability of the Chronocap™ pulsatile delivery device. 
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2. Materials and methods 
2.1. Materials 
Hydroxypropyl cellulose (HPC, Klucel® LF; Eigenmann & Veronelli, I); polyethylene 
glycol 1500 and 6000 (Clariant Masterbatches, I); colloidal grade Avicel® CL611 
microcrystalline cellulose (IMCD S.p.A, I); acetaminophen (AAP) fine powder 
(Atabay, TR) and granules (Compap™ Coarse L; Mallinckrodt, US); hard-gelatin 
capsules (DBcaps®, type B; Capsugel, US). 
 
2.2 Methods 
2.2.1. Rheological measurements 
The apparent viscosity of polymeric melts was measured using a Haake MiniLab II 
capillary rheometer (Thermo Scientific Haake, D). The microcompounder was 
equipped with conical co-rotating twin screws (diameter 5/14, length 109.5 mm) 
and a backflow channel (capillary: width 10 mm, height 1.5 mm, length 75 mm) 
with integrated pressure transducers. 5 g samples were manually fed into the 
extruder. At each extrusion temperature a 10 to 300 rpm screw speed ramp was 
used. All screw speeds were held for 60 s, and the pressure build-up of the 
material in the capillary was measured. For each formulation the extrusion 
temperature was varied from the minimum value that allowed torque ≤ 3.5 N·m 
to be registered up to 190 °C. 
Apparent viscosity data were fitted according to the power equation η=K·γn-1 
where η is the shear viscosity, γ is the shear rate, K and n are the consistency and 
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power-law index, respectively [Kontopoulou M., 2012]. The latter describes the 
thinning nature of the melt. 
A rotational plate (diameter 25 mm) rheometer (ARES, TA instruments, US) was 
also used to collect data under isothermal conditions (190 °C); time: from 0 to 
1400 s; frequency: 10 rad/s; strain: 0.2 %; gap 1 mm. 
 
2.2.2. Manufacturing of molded items 
Mixtures of HPC and polyethylene glycol 1500 were prepared in Turbula® (Type 
T2C, WAB, CH) and then transferred into a bench-top micromolding machine 
(BabyPlast 6/10P, Cronoplast S.L.; Rambaldi S.r.l., I). Before use, HPC was dried in 
a ventilated oven for 24 h at 40 °C. 
Molded items were prepared by means of two different molds: i) a disk-shaped 
mold (diameter: 30 mm; height: 1 mm) provided with a central gate and ii) a 
capsular mold with two interchangeable inserts for the manufacturing of 
matching cap and body items of 600 μm nominal thickness. The IM process 
conditions are reported in Table R1.1. 
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Table R1.1: IM process conditions. 
 Disk capsule 
 
 
 
compression zone temperature; °C 120-150 100 
metering zone temperature; °C 130-160 130 
nozzle temperature; °C 140-170 140 
hot runner temperature; °C - 160 
charge; mm 15-16 4 
1
st 
injection 
pressure; bar 50 30 
time; s 0.6 0.5 
rate; % 50 30 
2
nd 
injection 
pressure; bar 40 10 
time; s 2 0.3 
rate; % 40 10 
cooling temperature; °C 15 15 
cooling time; s 2.5 2.5 
closing pressure; bar 80 120 
opening rate; % 90 90 
 
2.2.3. Characterization of molded items 
Molded items, i.e. disks and assembled capsule shells, were checked for weight 
(analytical balance BP211, Sartorius, D; n = 10) and thickness (digimatic indicator 
ID-C112X, Mitutoyo, J; n = 10). Moreover, the height and diameter of assembled 
capsules were determined (analogical micrometer CD15D, Mitutoyo, J; n = 10). 
Digital photographs (Nikon D70, Nikon, J) of molded items were acquired. The 
mechanical properties of assembled capsule shells were evaluated by means of a 
TA.HD.plus Texture Analyzer (Stable Micro Systems, UK; n = 3) as previously 
described [Gazzaniga A. et al., 2011a]. Elastic modulus (Newton per square 
millimeter) was calculated from the initial linear portion of stress vs. strain 
curves. Percentage moisture content (MC %) of molded disks was calculated as 
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[(Ww-Wd)/Ww]·100, where Ww is the wet weight of the sample and Wd is its 
weight after drying (thermal-scale, Gibertini, I). 
The characterization of molded items was generally carried out immediately 
after ejection and after 1, 3 as well as 7 days storage at ambient conditions (24 ± 
2 °C / 55 ± 5 % RH). The mechanical properties and release performance of 
assembled capsule shells were evaluated after 7 days storage at ambient 
conditions. 
 
Evaluation of the release performance 
Capsule bodies were manually filled with differing formulations each containing 
50 mg of acetaminophen (AAP) as a tracer drug and closed with matching caps. 
For the release test (n = 6), an adapted six-position USP34 disintegration 
apparatus was used [Gazzaniga A. et al., 1995]. Each unit was inserted in a sinker 
and positioned in one of the six available tubes of the basket-rack assembly. The 
basket-rack assemblies moved at 31 cycles/min rate in separate vessels 
containing 900 mL water at 37 ± 0.5 °C. Fluid samples were withdrawn at fixed 
time points and assayed spectrophotometrically (248 nm). Lag time (t10%), i.e. the 
time to 10 % release, and pulse time (t90-10%), i.e. the time elapsed between 10 
and 90 % release, were calculated from the release curves. Sealing of the 
assembled capsules was avoided after verifying consistency in the performance 
of unsealed capsules and capsules sealed as previously reported [Gazzaniga A. et 
al., 2011a]. 
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Tracer drug formulations and relevant preparation: 
i) AAP fine powder (d10 = 14 μm; d50 = 29 μm; d90 = 58 μm) as such; 
ii) commercially available AAP granules with 90 % drug content (d10 = 230 μm; d50 
= 480 μm; d90 = 900 μm); 
iii) pellets in the 710-1000 µm dimensional range prepared by extrusion-
speronisation. AAP fine powder (50 % w/w) and microcrystalline cellulose, 
Avicel® CL611 (50 % w/w), were dry blended and granulated with water (45 % 
w/w with respect to dry powders) in a planetary mixer (KM 010, Kenwood, UK) 
fitted with a K-shaped mixing arm. Granulation was performed by slowly pouring 
water at a constant agitation speed of 250 rpm for 10 min. 350 mg of the wet 
mass was extruded by a radial basket apparatus (Nica® E140, GEA Pharma 
Systems, B) equipped with a multi-holed screen (internal hole diameter, 1 mm; 
screen thickness, 1.25 mm) and the resulting extrudates were spheronised in a 
Nica® S320 spheroniser with a 64 cm radial-hatched friction plate. Operative 
conditions were as follows: feeder speed, 90 rpm; extrusion speed, 70 rpm; 
spheronizer speed, 700 rpm; spheronization time, 1 minute. Pellets were dried in 
a vacuum oven at 40 °C for 24 h. 
iv) AAP solid dispersion in polyethylene glycol 6000 prepared by manually 
dispersing AAP fine powder (30% w/w) in the molten carrier at 60 °C. 
Capsular systems in which approximately 3 mg of a powder dye (methylene blue) 
was added to the filling formulations were analogously tested. The opening time 
of capsules was determined by visual inspection. It was defined as the time of 
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first rupture of the hydrated capsule shells highlighted by the very rapid 
dissolution of the dye inside the capsule. The morphological changes undergone 
by the capsular devices when exposed to aqueous fluids and the dissolution 
behavior of the dye were evaluated on units immersed in unstirred deionized 
water at the temperature of 37 ± 0.5 °C. Digital photographs were taken at 
successive time points. 
 
3. Results and discussion 
With the aim of developing a special mold, dedicated to the production of 
hydroxypropyl cellulose (HPC)-based capsules, and a robust injection molding 
(IM) manufacturing process, it was deemed necessary to focus on a single 
formulation and evaluate its thermal, rheological and mechanical characteristics. 
A previous promising composition based on Klucel® LF (KLF), plasticized with 
polyethylene glycol 1500 (PEG) to improve the mechanical properties of molded 
capsules, was thus selected as the starting formula [Gazzaniga A. et al., 2011a]. 
At first, the amount of plasticizer and the method of its incorporation (mixing 
process) appeared worthy of an in-depth investigation on account of their 
expected impact on the melt processability and the physical stability of molded 
items. The rheological properties of KLF melts with increasing amounts of PEG 
were thus evaluated by a twin-screw extruder integrated with pressure 
transducers in the backflow channel (capillary rheometer). Because of the 
relevant mixing ability, the use of co- or counter-rotating screws is well 
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established in the manufacturing of solid dispersions and of wet- or hot-melt 
extruded preparations [Repka M.A. et al., 2012; Fukuda M. et al., 2008]. 
Particularly lab-scale models, which allow to work with few grams of material 
(microcompounders), were also proposed as tools for rheological measurements 
since they may provide shear and extensional viscosity parameters at rates 
experienced during processing, especially when extrusion steps are involved (e.g. 
the plasticating phase of IM) [Cheng B. et al., 2001; Chen Z. et al., 2006; Chen Z. 
et al., 2008; Ralston B.E. and Osswald T.A., 2008]. Indeed, it is well known that 
the viscosity characteristics may affect the processability of polymeric melts. 
Formulations with viscosity values ranging between 103 and 104 Pa·s at 
operating temperatures are generally used for extrusion processes, whereas 
lower viscosities (from 101 to 5x102 Pa·s) are needed to face the small cross-
sections and/or long flow path entailed by IM [Klemens Kohlgrüber H., 2008]. 
Polymeric melts are usually characterized by a shear-thinning (or pseudoplastic) 
behavior that is evident from shear stress vs. shear rate profiles. By employing 
screw-driven capillary rheometers (such as the microcompounder used), shear 
stress profiles can be obtained as a function of the screw rotation speed thus 
allowing apparent viscosity values to be calculated [Bialleck S. and Rein H., 2011]. 
In Figure R1.1, rheograms relevant to KLF as such or in admixture with 5, 10 and 
15 % by weight (wt %) of PEG (with respect to the amount of polymer) at 
different temperatures are reported. Different ranges of processing 
temperatures were taken into account. The lower limit was that defined by the 
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resistance of the screw to rotation (torque values ≤ 3.5 N·m). On the other hand, 
even though the higher limit was set at 190 °C, only data relevant to 
temperatures ≤ 170 °C were considered because of a browning tendency of the 
polymer that was highlighted beyond such a value [Gazzaniga A. et al., 2011a]. 
 
 
 
Figure R1.1: Apparent viscosity profiles of Klucel® LF melts at different 
temperatures: polymer as such (a) and plasticized with 5 (b), 10 
(c) or 15 % (d) of PEG. 
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As expected, the apparent viscosity of KLF-based melts was largely influenced by 
temperature, especially at the low share rates. Rheograms of the plasticizer-
containing mixtures showed an analogous trend as the polymer as such, 
although apparent viscosity was generally reduced. Moreover, the addition of 
increasing amounts of PEG was demonstrated to improve the flow behavior of 
the melts thus allowing the latter to be extruded at progressively lower 
temperatures (up to 110 °C in the case of 15 % PEG formulation). 
In the range of shear rates considered, the shear flow is known to be well 
described by the power-law equation. Hence, it was thereby possible to calculate 
the relevant parameters, n and K [Kontopoulou M. et al., 2012; Paradkara A. et 
al., 2009]. The power-law index n describes the thinning nature of the melt (i.e. 
the smaller the value of n, the more shear-thinning the melt), whereas K is a 
consistency index representing the hypothetical shear viscosity extrapolated to 
zero wall shear rate. The fitting parameters of the above-discussed viscosity 
profiles are reported in Table R1.2. 
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Table R1.2: Calculated power-law parameters (n, K and regression coefficient R2) 
relevant to Klucel® LF-based melts at different temperatures. 
 
 amount of plasticizer, wt % 
 0 5 10 15 
°C n K R2 n K R2 n K R2 n K R2 
110 nd Nd nd nd nd nd nd nd nd 0.13 41037 0.968 
120 nd Nd nd nd nd nd 0.14 35406 0.977 0.20 22124 0.989 
130 nd Nd nd 0.21 16650 0.991 0.30 7332 0.989 0.30 7113 0.996 
140 0.26 11026 0.969 0.35 3659 0.992 0.37 2657 0.996 0.37 2510 0.998 
150 0.34 4322 0.993 0.38 1644 0.997 0.37 1766 0.999 0.34 2136 0.999 
160 0.40 1706 0.998 0.40 1099 0.999 0.43 1043 0.997 0.35 1500 0.999 
170 0.41 1026 0.999 0.42 747 0.999 0.40 820 0.999 0.32 1721 0.999 
 
Good correlation coefficients were always obtained, and n values were in 
agreement with those reported in the literature for the same type of polymer 
[Paradkara A. et al., 2009]. The rheological parameters were determined under 
temperature conditions analogous to those expected during IM processes 
though necessarily at lower shear rates. Data should therefore be considered 
descriptive of the melt behavior from a merely qualitative point of view. In this 
respect, interesting remarks were drawn from the comparative evaluation of the 
results obtained. Firstly, the shear-thinning nature of the molten polymer was 
confirmed to progressively decrease in the temperature range from 140 °C (n 
value 0.26) to 170 °C (n value 0.41). Analogously, it was reduced by addition of 5 
% of plasticizer at any temperature. However, increasing the amount of this 
excipient, in particular from the 10 to 15 % PEG-containing formulation, an 
opposite tendency was observed, especially at the higher temperatures. As far as 
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the consistency index K is concerned, it is known to depend on the degree of 
polymeric chain mobility and was accordingly supposed to also vary with the 
temperature and extent of plasticization. K values decreasing from the lower to 
the higher processing temperature were generally obtained for all the 
formulations except the one containing 15 % of PEG at 170 °C. Moreover, at all 
the operating temperatures, K was higher for the polymer as such than for the 
PEG 5% formulation. However, by rising the amount of PEG, an opposite and 
unexpected tendency to increase was noticed for K at temperatures > 140 °C, 
which could be ascribed to a chain rearrangement or a mechanically- and/or 
thermally-induced degradation of the polymer [Yan D. et al., 1999]. Indeed, the 
molten KLF and the 5 as well as 10 % PEG formulations also showed a similar 
behavior, i.e. an increase in K, though only above 170 °C (data not shown). These 
results were confirmed by complex viscosity data obtained under isothermal 
conditions at 190 °C that, for all the formulations, exhibited an increasing trend 
over time. By way of example, patterns relevant to the 10 % PEG formulation are 
reported in Figure R1.2. 
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Figure R1.2: Absolute viscosity (red diamonds), G’ storage modulus (blue 
triangles), G’’ loss modulus (green squares) and G’’/G’ tan-delta 
(black diamonds) profiles of KLF melt with 10% of PEG. 
 
The overall results of rheological studies demonstrated the need for dealing with 
a plasticized KLF formula in order to improve not only the mechanical properties 
of molded items but also the processability of the melt. Moreover, they indicated 
that not only operating temperatures would be a critical issue, but also the time 
over which the material is maintained at a relatively high temperature that is 
related to the IM process cycle time. In order to avoid overheating, special 
changes were introduced into the press configuration, such as a reduction in the 
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diameter of the piston and nozzle so that the amount of material heated at each 
molding cycle, i.e. the mean residence time of the material under heating, was 
minimized. 
The influence of the operating temperatures and amount of plasticizer on the 
actual IM processability and on the characteristics of molded products was then 
investigated. In particular, the dimensional changes (contraction or expansion) 
undergone by the item inside the mold, immediately after demolding or in the 
successive hours/days, needed to be considered because they may impair the 
relevant quality and performance, and might also have an impact on the design 
of the mold cavity [Fischer J.M., 2003]. Disk-shaped items (1 mm thickness and 
30 mm diameter) especially suitable for the evaluation of dimensional changes 
(shrinkage test) were therefore prepared [Zema L. et al., 2013], providing the 
modified press with a centrally-gated circular mold. A 120-170 °C range of 
temperatures was investigated setting a 10 °C-based ramp. Different 
combinations of compression, metering and nozzle temperatures were thus 
considered, namely from 120/130/140 °C to 150/160/170 °C. The change in the 
operating temperatures only involved a minimal adjustment of all the other 
process parameters. Moreover, the effect of the amount of plasticizer on 
processability was limited to a slight sticking tendency observed with the 15 % 
PEG formulation. With regard to the physico-mechanical characteristics of 
molded items, while no significant influence of the manufacturing temperature 
was noticed, the degree of plasticization was confirmed as a critical aspect. In 
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particular, the molded items containing only 5 % of PEG turned out glassy and 
brittle but maintained their shape after demolding, whereas in the presence of 
higher amounts of plasticizer deformation of the disks occurred. By way of 
example, data relevant to molded disks obtained under a mid-range combination 
of temperatures (i.e. 140/150/160 °C) are shown in Table R1.3. 
 
Table R1.3: Characteristics of molded disks (standard deviation in brackets); scale 
bar of photographs =           5 mm. 
 
% of PEG  weight 
mg 
thickness 
µm 
 moisture content 
%  
t = 0 t = 0 
t = 72 
h 
t = 72 h t = 0 
t = 72 
h 
t = 7 
days 
5 
937.57 
(1.24) 
1080 
(5) 
1121 
(12) 
 
1.7 
(0.12) 
4.5 
(0.42) 
5.5 
(0.48) 
10 
931.86 
(2.57) 
1078 
(8) 
1118 
(10) 
 
1.5 
(0.21) 
4.2 
(0.45) 
4.5 
(0.53) 
15 
927.88 
(3.61) 
1087 
(13) 
1117 
(15) 
 
1.1 
(0.15) 
2.9 
(0.32) 
3.7 
(0.58) 
 
KLF-based molded disks generally showed an increment of thickness, with 
respect to the mold nominal dimension, of about 8 %, increasing up to 12 % over 
72 hours. The degree of plasticization was demonstrated not to have a significant 
influence on the final disk thickness (p < 0.1). On the contrary, the molded disks 
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exhibited a warping tendency that could be related to the amount of plasticizer 
in the formulation. Indeed, only with the items containing PEG at 5 %, bending 
was observed neither after demolding nor storage. According to previous 
findings relevant to HPC-based capsular devices prepared by IM [Gazzaniga A. et 
al., 2011a], the molded disks reached a re-equilibrium in terms of moisture 
content within 7 days of storage at ambient conditions from preparation, 
whereas no dimensional changes were highlighted after 72 h. 
Taking the overall results obtained into account, a novel mold for the production 
of capsular devices with 600 μm thickness was specially designed for use with 
the 10 % PEG formulation, improved in that: i) a centered position of the 
injection orifice would enable a consistent flow length in all directions, ii) a hot 
runner keeping the melt heated up to the mold cavity would prevent 
overheating of the material thanks to the possibility of maintaining the desired 
temperature while this is moving throughout the mold, iii) a halved thickness in 
the body/cap contact areas would lead to a constant thickness of the closed 
device also in the overlap region, iv) a length/diameter ratio lowered to 1.5 
would reduce the flow path of the melt inside the unheated mold cavity, and v) a 
duct for injection of compressed air into the mold would facilitate the ejection of 
the molded item thus allowing the use of lubricants to be avoided. The amount 
of plasticizer selected was the minimum able to improve the KLF melt 
processability and the molded item brittlness. The process parameters required 
to be defined by means of preliminary trials. By the selected operating 
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conditions, a fully automated process was finally achieved with a cycle time per 
cap or body item reduced to about 5 s and no need for adding either internal or 
external lubricants (Table R1.1 in the Material and methods section). The highest 
temperature of 160 °C was set in the final step only, i.e. in the hot runner, 
whereas the plasticating/injecting phases of the process could be carried out at 
lower temperatures. An outline and some pictures of the capsule shells obtained 
are shown in Figure R1.3. 
 
 
 
Figure R1.3: Technical drawing and photographs of the capsular device. 
 
The capsules manufactured by using the novel mold were evaluated in terms of 
technological properties and release performance. When comparing such units 
with those prepared by the former mold, the average shell thickness turned out 
closer to the nominal 600 μm value and, importantly, the extent of thickness 
variability was considerably restrained (Table R1.4). This result was also reflected 
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in a higher reproducibility of the mechanical properties of the shells as expressed 
by elastic modulus (EM). Probably because of their modified shape, the novel 
capsules exhibited a lower EM. However, this was still comparable with that of 
immediate-release gelatin capsules thus supporting the possible utilization of the 
filling equipment employed for the latter [Gazzaniga A. et al., 2011a]. 
 
Table R1.4: Physico-technological characteristics of capsule shells prepared by 
the novel and the former mold (CV in brackets); data for the former 
devices are adapted from [Gazzaniga A. et al., 2011a]. 
 
 Capsule shells prepared by the 
 novel mold former mold 
Weight, mg 228 (0.51) 336 (0.70) 
Height, mm 13.11 (0.13) 16.08 (0.12) 
Diameter, mm 8.05 (0.02) 8.19 (0.37) 
Thickness, µm 610 (3.30) 645 (13.20) 
Elastic modulus, N/mm
2
 3.509 (2.01) 5.342 (15.72) 
 
Furthermore, the ability of the HPC capsule-based devices to impart a lag phase 
to the release of their content was investigated, and the relevant release profiles 
were comparatively evaluated vs. the dissolution curves of gelatin capsule 
dosage forms with an analogous filling. In particular, acetaminophen (AAP) was 
selected as a tracer drug, and formulations with a possibly different dissolution 
behavior were considered, namely fine powder, commercially available granules, 
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microcrystalline cellulose-based pellets prepared by extrusion-spheronization 
and a solid dispersion of the fine powder in polyethylene glycol 6000. Moreover, 
particular HPC capsule devices that also contained a dye were tested under 
analogous hydrodynamic conditions and in an unstirred medium in order to 
assess the rupture mode (time and position) of the shell. 
Important information was drawn from the evaluation of the morphological 
changes undergone by the HPC capsule-based devices when exposed to aqueous 
unstirred fluids and of the dissolution behavior highlighted by the dye-containing 
fillings. The capsule shells remained intact during the hydration and 
dissolution/erosion of the external polymeric layers, independent of the 
contents. The first rupture of the device took place in the cap item at the 
cap/body overlap region, where the body wall ends. A very rapid dissolution of 
the dye inside the capsule, before its contents were quantitatively delivered, 
demonstrated that aqueous fluids initially diffuse into the shell cavity through 
this cleft. An opening time was thus defined. By way of example, photographs of 
the device containing the fine powder formulation are reported in Figure R1.4. 
Such a behavior of HPC-based systems was confirmed under the conditions used 
for the release test and opening times were determined. 
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Figure R1.4: Photographs of a capsular device, containing AAP fine powder along 
with methylene blue, taken at successive time points (< 1 min 
intervals) during immersion in unstirred deionized water.  
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The dissolution and release profiles from gelatin and KLF capsule-based systems, 
respectively, are reported in Figure R1.5. The obtained data of opening time, 
along with those of lag time before drug release (expressed as t10%, time for 10 % 
of drug to be released) and pulse time, i.e. the time elapsed between onset and 
completion of the release process (expressed as t90-10%), relevant to the profiles 
of Figure R1.5 are collected in Table R1.5. For comparison purposes, t10% and t90-
10% values were analogously calculated from the dissolution profiles of gelatin 
capsule-based dosage forms. 
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b)  
 
Figure R1.5: Dissolution/release profiles of gelatin (a) or HPC (b) capsule-based 
systems containing different AAP formulations. 
 
Table R1.5: Release parameters of gelatin and HPC capsule-based systems 
containing different AAP formulations (standard deviation in 
brackets). 
filling formulation 
gelatin capsule-based systems HPC capsule-based systems 
lag time 
min  
pulse time 
min  
opening time
*
 
min  
lag time 
min  
pulse time 
min  
fine powder 3.5 (0.1) 3.8 (1.1) 33 (1) 36.0 (1.3) 5.0 (1.0) 
granules 3.5 (0.1) 4.3 (0.9) 35 (2) 32.6 (3.1) 5.1 (0.5) 
Pellets 6.6 (0.5) 8.7 (1.7) 35 (1) 45.0 (2.9) 13.9 (5.6) 
solid dispersion 4.9 (1.2) 5.1 (1.1) 34 (2) 41.7 (3.1) 13.9 (0.9) 
* 
determined by visual inspection from HPC capsule-based devices that contained a dye added to 
the filling 
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The HPC capsular containers developed proved able to achieve a lag phase prior 
to drug release. Moreover, the opening time was independent of the filling. On 
the other hand, some minor differences were found in the release parameters, 
such as in particular extended lag and pulse times of capsules filled with pellets 
or with the solid dispersion, which could be attributed to the dissolution 
behavior of these particular formulations. Indeed, while from the fine powder 
and the granules, containing disintegrant and wetting agents, the drug tracer 
was promptly available for dissolution, its contact with the aqueous fluid was 
somewhat delayed because of the reduced surface area exposed by highly dense 
matrix pellets made of microcrystalline cellulose and coarse fragments of the 
solid dispersion [Zema L. et al., 2008]. An analogous trend was observed with 
gelatin-based dosage forms with the same contents. With respect to the capsular 
devices prepared by the former mold, the duration of release (pulse time) was 
reduced probably due to the relatively lower amount of polymer that has to 
erode/dissolve to enable the breakup of the capsule. 
In order to explore whether the method of preparation of KLF blends with 10 % 
of plasticizer would impact on the IM process, capsule shells were prepared 
starting from pre-extruded KLF/PEG blends obtained under different 
temperatures; no influence on the manufacturing (process conditions, cycle 
time) nor on the physico-technological characteristics of the capsules was 
thereby highlighted (data not shown). 
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4. Conclusions 
An oral capsular device (Chronocap™) intended for pulsatile and/or time-based 
colonic delivery was recently prepared by injection molding (IM). The prototype 
capsule shells obtained from a swellable/erodible thermoplastic polymer (HPC) 
were able to delay, both in vitro and in vivo, the release of a model drug. The lag 
phase duration was found dependent on the shell composition and wall 
thickness. In the prospect of a scale-up of this technology, the development of a 
novel mold and manufacturing process was pursued in order to improve the 
technological characteristics of capsules on the one hand (e.g. shell thickness 
variable and poorly consistent with the nominal value), and the production rate 
as well as extent of automation on the other. The capsular devices prepared by 
this mold through an automatic manufacturing cycle (duration 5 s) were 
demonstrated to possess good technological properties and, as compared with 
the previous systems, higher reproducibility of shell thickness, mechanical 
properties, opening mechanism and release performance. In particular, although 
filled with different drug formulations, they showed a reproducible time to 
breakup (opening time) that was followed by release patterns dependent on the 
dissolution behavior of their contents. 
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Enteric-Coating of Pulsatile-Release Capsules Prepared by Injection Molding 
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Abstract  
Erodible capsular devices based on hydroxypropyl cellulose (Klucel® LF) intended 
for pulsatile release were prepared by injection molding (IM). In the present 
work, the possibility of exploiting such capsules for the development of colonic 
delivery systems based on a time-dependent approach was evaluated. For this 
purpose, it was necessary to demonstrate on the one hand the ability of molded 
cores to undergo a coating process and, on the other, that of coated systems to 
yield the desired performance (gastric resistance). Although no information was 
available on the coating of IM substrates, some issues relevant to that of 
commercially-available capsules are known. Thus, preliminary studies were 
conducted on molded disks for screening purposes prior to facing the spray-
coating of HPC capsular cores with Eudragit® L 30 D 55. The ability of the 
polymeric suspension to wet the molded substrate, spread above it, start 
penetrating and bring about hydration/swelling phenomena, as well as to 
provide a gastroresistant barrier was demonstrated. The coating of prototype 
HPC capsules was carried out successfully, leading to coated systems with good 
technological properties and able to withstand the acidic medium with no need 
for a sealing. Such systems maintained the original pulsatile release performance 
after failure of the enteric film in pH 6.8 fluid. Therefore, they appeared 
potentially suitable for the development of a colon delivery platform based on a 
time dependent approach. 
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Keywords: injection molding; capsular device; enteric coating; oral pulsatile 
release; oral colon delivery; swellable/erodible polymers. 
 
1. Introduction 
In the field of oral delivery, besides a widespread use of prolonged-release 
dosage forms [Grassi et al., 2004; Sangalli et al., 2001b], increasing interest has 
been focused on the development of formulations able to release active 
pharmaceutical ingredients after programmed lag times [Conte et al., 1989; 
Maroni et al., 2013b, 2010] or to specific regions of the gastrointestinal (GI) tract 
[Pinto, 2010]. In particular, the possibility of exploiting the colon as a site for the 
release of drugs for the treatment of both local and systemic pathologies has 
been investigated: while several applications for the management of local 
symptoms/pathologies (e.g. inflammatory bowel disease, IBD) can be already 
found in the literature, colon delivery is currently considered an interesting 
approach for increasing the bioavailability of peptides and proteins [Maroni et 
al., 2013a, 2012]. The colon has long been considered an unsuitable site for the 
absorption of molecules because of the reduced surface area; moreover, the lack 
of free fluids, the viscous contents and the presence of gas produced by bacterial 
fermentation processes may impair the disintegration of oral dosage forms and 
dissolution of drug particles. However, the unfavorable anatomical and 
physiological characteristics of the colon are offset by its low concentration of 
local peptidases and the long residence time of drug delivery systems.  
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Over the years, several strategies have been attempted for targeting the colonic 
region. The exploitation of enzymatic reactions by unique bacteria at the site is 
one (chemical/microbiological approach): among substrates undergoing 
enzymatic activation reactions (i.e. reduction and hydrolysis of azo and glycoside 
bonds, respectively), both prodrugs and polymeric materials have been 
investigated [Patel and Amin, 2011]. The high variability in the composition of 
the microflora, influenced by everyday events (e.g. stress, modification of the 
diet and concurrent therapies), regulatory burden involved by the use of 
prodrugs and synthetic materials as well as poorly reliable performance of 
natural polysaccharide carriers represent the main critical aspects of this delivery 
strategy. The technological/physiological approach, on the other side, makes use 
of the difference in some parameters along the GI tract, namely pressure, pH or 
transit time. With the pressure-controlled delivery strategy, the disintegration of 
the drug delivery system is enhanced by the combination between intense 
muscle contractions and the higher viscosity of luminal contents [Takaya et al., 
1995]. The pH-based approach relies on the hypothesis of a progressive increase 
in the pH values along the GI tract. Relevant systems are composed of a drug-
containing core coated with polymers which dissolve in media with neutral to 
weakly alkaline pH. However, the possibility that this pH threshold is exceeded in 
the small intestine or a weakly acidic pH is found in the caecum and in the right 
colon segments may lead to an inconsistent performance of devices [Gazzaniga 
et al., 2006]. Finally, the time-dependent approach to colon delivery is based on 
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the relatively constant small intestinal transit time (SITT; 3 h ± 1 standard error) 
of dosage forms [Davis, 1985]. On the contrary, the duration of gastric residence 
of solid dosage forms, which depends on their size and density as well as fasted 
or fed conditions of subjects, is unpredictable; hence, by the application of an 
outer gastroresistant layer, which dissolves after the dosage form is emptied 
from the stomach, the variability in gastric emptying can be overcome. 
Subsequently, a lag phase imparted to the drug-containing core allows the 
system to reach a delay duration comparable to SITT, thus targeting the colonic 
region of the GI tract [Gazzaniga et al., 2006]. 
Among time-based devices for colonic release, a platform for delayed and site-
specific release of drugs in the form of a reservoir system, named Chronotopic™, 
has already been developed [Del Curto et al., 2011, 2009; Sangalli et al., 2004, 
2001a; Zema et al., 2007]. Such device is based on single- or multiple-unit drug 
cores (tablets, capsules, pellets) coated with a functional layer composed of 
swellable/erodible polymers (namely, hydroxypropyl methylcellulose, HPMC) of 
few hundreds microns of thickness applied by different techniques (press-
coating, spray-coating and powder layering). When intended for time-based 
colon delivery, an outer enteric film is subsequently applied. Once the device is 
emptied from the stomach, the enteric coating dissolves and the HPMC-based 
layer delays the contact of the biological fluids with the core, allowing the 
release of the drug only after a programmed period of time. The effectiveness of 
the Chronotopic™ system, its flexibility in terms of duration of the lag phase, 
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both in vitro and in vivo, as well as the possibility of scaling up the manufacturing 
process has been widely demonstrated. A step forward in the development of 
the Chronotopic™ system was represented by a capsular device (Chronocap™) 
that combined the release functionality of the polymeric coating with the ability 
to convey a variety of drug preparations (solid, semi-solid, liquid), thus bringing 
about both technical and regulatory advantages. The feasibility of the injection 
molding (IM) technique to prepare capsules from a thermoplastic swellable ether 
of cellulose, hydroxypropylcellulose (HPC), as an alternative to the HPMC-based 
coating of the Chronotopic™ delivery platform, has previously been 
demonstrated [Gazzaniga et al., 2011; Zema et al., 2012].  
Preliminarily, shells of different thickness (300, 600, and 900 µm) were prepared 
and showed good technological characteristics. Moreover, pulsatile release 
patterns were obtained from drug-containing capsules, both in vitro and in vivo, 
with a lag time that was dependent on the shell composition and thickness 
[Zema et al., 2013a]. In the prospect of an industrial scale up, a purposely 
devised mold with a nominal thickness of 600 µm was designed on the basis of 
thermal, rheological and mechanical characteristics of the polymeric formulation 
selected [Zema et al., 2013b]. The new mold allowed a fully automated 
manufacturing to be developed with cycle times of few seconds. However, no 
information is available on the application of pharma-grade polymer coatings 
onto the molded HPC capsule shell devices. 
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Based on these premises, the aim of the present work was to evaluate 
Chronocap™ capsules as cores for the application of a gastroresistant film, in 
order to make them possibly suitable for the development of a time-dependent 
colonic release system. The feasibility of coating IM capsules with an aqueous-
based enteric dispersion (Eudragit® L 30 D-55) was preliminarily studied using a 
prototype shell of 600 µm thickness composed of Klucel® LF plasticized with 
polyethylene glycol (PEG 1500, 10 % by weight) and filled with a tracer drug. 
 
2. Materials and methods 
2.1. Materials 
Hydroxypropyl cellulose (HPC): Klucel® LF, Eigenmann & Veronelli, Italy; 
hydroxypropyl methylcellulose (HPMC): Methocel™ E50 Premium LV, Dow, Italy; 
polyethylene glycol (PEG) 1500, Clariant Masterbatches, Italy; low-density 
polyethylene (LDPE), Polimeri Europa, Italy; acetaminophen (AAP) fine powder, 
Atabay, Turkey; Eudragit® L 30 D-55, Evonik, Germany; triethyl citrate (TEC), 
Vertellus Specialties Inc., IN, USA; fluorescein sodium salt, Sigma-Aldrich Corp., 
MO, USA; size 2 hard-gelatin and HPMC capsules, Capsugel, SC, USA. 
 
2.2. Methods 
2.2.1. IM processes 
A mixture of HPC, previously dried in a ventilated oven for 24 h at 40 °C, and PEG 
1500 (90 % and 10 % w/w, respectively) was prepared in Turbula® (Type T2C; 
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WAB, Switzerland) and then transferred into a bench-top micromolding machine 
(BabyPlast 6/10P; Cronoplast S.L., Spain; Rambaldi S.r.l., Italy). Molded items 
were prepared by means of two different molds: (1) a disk-shaped mold 
(diameter: 30 mm; height: 1 mm) provided with a central gate and (2) a capsular 
mold with two interchangeable inserts for the manufacturing of matching caps 
and bodies of 600 µm nominal thickness. Process conditions were applied as 
reported in [Zema et al., 2013b]. Disks made of LDPE were also prepared. 
The physical characteristics, mechanical properties and release performance of 
capsule shells were evaluated after 7 days of storage at ambient conditions (24 ± 
2 °C / 55 ± 5 % relative humidity). 
 
2.2.2. Capsules filling 
Gelatin, HPMC and HPC-based capsule shells were manually filled with 80 mg of 
AAP. Banded samples of each type of system were prepared: gelatin capsules 
were manually sealed with a 20 % w/v gelatin aqueous solution, HPMC with a 
20% w/v Methocel™ E50 aqueous solution and HPC-based capsules with a 3 % 
w/v Klucel® LF aqueous solution. 
 
2.2.3. Coating processes 
2.2.3.1. Preparation of the coating suspension and fluorescein solution  
The coating suspension was prepared by dissolving TEC (20 % w/w, based on the 
dry polymer weight) into the commercially available Eudragit® L 30 D-55 
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dispersion, previously diluted to decrease the solid contents to 20 %; when 
required, fluorescein (0.01 % w/w, based on the dry polymer weight) was added. 
The suspension was stirred for at least 30 min, filtered through a 0.3 mm sieve 
and maintained under stirring during the coating process. 
A solution of fluorescein alone for comparison purposes was prepared by 
dissolving the fluorescent marker in pure water at the same concentration used 
in the coating suspension. 
 
2.2.3.2. Coating of molded disks and glass slides 
The coating suspension containing fluorescein was sprayed by a two-fluid nozzle 
(Series 970, Düsen-Schlick, Germany) with 1.2 mm port size onto a rotating 
drum, carrying disks and glass slides, covered by a siliconized liner under a 
constant heating air flow in order to maintain the film surface at approximately 
30 °C [Felton, 2007]. Each sample was sprayed with the amount of suspension 
needed to reach theoretical 10 mg/cm2 of polymer applied. Molded HPC-based 
disks were sprayed under the same conditions with the fluorescein solution for 5 
s. 
 
2.2.3.3. Coating of capsules 
Batches of 500 capsules, both banded and unbanded, were coated in a Hi-coater 
(Vector corporation LDCS-3, Vector Corp., IA, USA) equipped with a 1.3 L 
perforated pan. Process conditions were: inlet air temperature, 30 °C; air 
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pressure, 12 psi; pan speed, 15 rpm; spraying rate, 1 g/min. For HPC capsules 
only, the spraying rate was also increased up to 2 g/min. During the process, 
samples with different coating levels were withdrawn and replaced with placebo 
capsules to maintain the batch size.  
 
2.2.3.4.Curing 
After the coating process, all samples (glass slides, disks and capsules) were 
cured in a ventilated oven at 40 °C for 2 h. In order to allow re-equilibrium with 
ambient humidity, all measurements were performed after 7 days of storage at 
ambient conditions (24 ± 2 °C/55 ± 5 % RH) from preparation. 
 
2.2.4. Characterization of substrates and coated systems 
2.2.4.1. Contact angle  
A Tantac CAM-Micro Contact Angle Meter (Chemsultants International, Inc., OH, 
USA) was used to determine contact angles between the Eudragit® L 30 D-55 
suspension and different substrates: HPC-based molded disks, LDPE molded disks 
and glass slides. A 10 µl droplet of the polymeric suspension was delivered onto 
the surface of each substrate and contact angles were measured after 1 s and 15 
s (n = 3). 
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2.2.4.2. Gastroresistance and release performance 
Uncoated substrates (molded disks and capsules) were tested in phosphate 
buffer pH 6.8 according to the Dissolution Test for Immediate-Release Dosage 
Forms (USP 34); coated systems (glass slides, molded disks and capsules) were 
tested according to the Dissolution Test for Delayed-Release Dosage Forms, 
Method A for HPC-based capsules and Method B in all other cases; n = 3. 
Molded disks were fixed to an inert support in order to avoid floating during the 
test: pre-weighed samples were dried in a ventilated oven at 40 °C for 2 h and 
then transferred into a USP 34 Apparatus 2; test conditions: 900 mL of 
dissolution medium (HCl 0.1 N, pH 1.2 or phosphate buffer, pH 6.8), 37 ± 0.5 °C, 
50 rpm. At fixed time intervals, samples were withdrawn from the medium and 
dried in a ventilated oven at 40 °C for 24 h. The residual dry mass was calculated 
from the dried (mdried) to starting (m0) mass ratio according to Eq. (1): 
 
Residual dry mass % = 100 - [(mdried/m0) * 100]                                   Eq. (1) 
 
Conventional capsules (gelatin and HPMC) were tested in Apparatus 2, at 50 
rpm, in 900 ml of medium at 37 °C with wire sinkers. IM capsules were tested in 
a six-position USP 34 disintegration apparatus in order to avoid sticking of the 
swollen shells to the vessels [Gazzaniga et al., 2011, 1995]: each unit was 
inserted in one of the six available tubes of the basket-rack assembly, moving at 
31 cycles/min rate in separate vessels that contained 675 mL of dissolution 
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medium (HCl 0.1 N, pH 1.2 or 800 mL phosphate buffer, pH 6.8), 37 ± 0.5 °C (n = 
3). Fluid samples were spectrophotometrically assayed at 248 nm. 10 % drug 
dissolved/released (t10%) was calculated from the relevant curves, that was 
defined as the lag time in the case of HPC capsules. Moreover, the time elapsed 
between 10 % and 90 % release was calculated from the profiles of HPC-based 
systems that was defined as pulse time (t90%–10%). 
 
2.2.4.3. Dimensions 
The diameter of uncoated capsules and coated systems was determined by 
micrometer (Craftsman Micrometer, Mechanical Digital, 0-1 in. range, n = 10). 
The coating layer thickness was calculated from the difference between 
diameters of coated (dc) vs. uncoated (duc) capsules according to Eq. (2):  
 
Coating thickness = (dc - duc)/2                                                                    Eq. (2) 
 
2.2.4.4. Mechanical resistance 
The mechanical properties of uncoated and coated HPC-based capsules were 
evaluated (n = 3) using a Chatillon universal tension/compression tester (model 
TCD-200 MS, Wagner Instruments, CT, USA) equipped with a DFGS digital force 
gauge and a flat-ended probe with 13 mm diameter. Capsular samples were 
placed on the lower stationary platform, centrally positioned under the probe 
[Missaghi et al., 2006]; the upper platen was then lowered and compressed the 
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capsule at a rate of 10 mm/min. Capsule failure under crushing was determined 
and the inherent load strength (N) was measured. 
 
2.2.4.5. Moisture sorption 
Uncoated disks and disks coated with up to 10 mg/cm2 of dry polymer were 
analyzed by means of a dynamic vapor sorption apparatus (DVS Advantage-1, 
Surface Measurement Systems Ltd., UK). Pre-weighed samples of about 50 mg 
cut from disks were added to 10 mm video quartz pans, which were placed in the 
sample chamber. Experiments were conducted isothermically (either 25 or 40 °C) 
under N2 purge of 200 sccm. Samples, initially dried at 0 % RH until a dm/dt of 
0.002 %/min was reached, were then exposed to a ramping experiment from 0 % 
to 98 % RH in 600 min. Finally, each sample was equilibrated at 98 % RH, 
determined by a dm/dt of 0.002 %/min. 
 
2.2.4.6. Photographs 
Digital photographs of molded disks uncoated and coated up to 10 mg/cm2 of 
dry polymer were acquired by a Nikon D70 camera (Nikon, Japan). 
Samples of glass slides and molded disks treated with the fluorescein-containing 
solution or suspension and tested for gastroresistance were analyzed by confocal 
laser scanning microscopy (CLSM). Images were taken with a Zeiss LSM 510 
camera (ZEISS, Germany) coupled with a microscope (AxioPlan 2 MOT, ZEISS, 
Germany); a ×20 objective lens (Numerical Aperture 0.5) was used and laser 
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excitation wavelength was set to 488 nm. Single plane images of the surface of 
samples and optical cross sections were acquired. 
Photomicrographs of gelatin, HPMC and HPC-based capsules, uncoated and 
coated up to 10 mg/cm2 of dry polymer were taken by a Jeol Model 35 scanning 
electron microscope (Jeol, MA, USA); details of the surface and of the cap and 
body closing area were acquired. 
Photomicrographs of HPC-based capsules were taken by an optical microscope 
(Inverted Olympus 1x70, Olympus, PA, USA) coupled with a camera (Olympus 
DP2-BSW, Olympus, PA, USA); details of the cross section of capsule cleaved by 
means of a scalpel were acquired. 
 
3. Results 
With the aim of demonstrating the feasibility of a colonic delivery system based 
on the Chronocap™ platform, the coating of a molded prototype with a gastro-
resistant polymer (Eudragit® L 30 D-55) was investigated. Data relevant to the 
characterization of HPC-based capsules as a substrate for coating processes, the 
development of the coating process itself and the evaluation of coated capsules 
compared with conventional gelatin or HPMC ones are reported. 
 
3.1. Characteristics of core units 
In order to develop a coating process for molded HPC capsules, some critical 
issues related to other types of capsule cores needed to be considered. For 
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example, the smooth surface of the shell of hard gelatin capsules may lead to 
poor adhesion of the coating film [Nagata, 2002]; moreover, during the initial 
phase of wetting, partial solubilization of gelatin may result in sticky shells 
[Thoma and Bechtold, 1992], whereas shell brittleness was noticed after 
exposure to low humidity conditions [Osterwald, 1982]. In addition, the 
irregularity of the closing area could prevent the formation of a continuous layer 
[Felton et al., 2002; Plaizier-Vercammen et al., 1992]. Some of these drawbacks 
were partly overcome by using a subcoat that, however, involves a further 
process step, potentially problematic and time consuming. More recently, 
HPMC-based capsules were launched on the market as an alternative to gelatin-
made ones for meeting vegetarian needs and incompatibility problems [Ogura et 
al., 1998]. As these capsules are composed of a non-ionic polymer, they 
demonstrated less reactivity toward many chemical entities (e.g. aldehydes, 
reducing sugars and metal ions) and a higher compatibility with some filling 
vehicles (including liquids) in comparison with hard gelatin capsules. 
Furthermore, the mechanical strength of the HPMC shells was shown to be less 
influenced by storage humidity conditions [Sherry Ku et al., 2010]. Finally, such 
capsules showed a rougher surface with respect to gelatin shells, suggesting a 
potential for better film adhesion, although the need for a sealing step was 
demonstrated [Cole et al., 2002; Felton et al., 2002; Sherry Ku et al., 2010]. 
As mentioned, little information is available about the impact of the IM process -
i.e. of high temperatures and pressures applied to the polymeric formulation in 
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order to have it melt and flow through a relatively long narrow mold section- on 
the properties of the material (e.g. surface characteristics, porosity, hydration 
rate and swelling ability). Therefore, the ability of a Eudragit® L 30 D-55 coating 
suspension to adhere to molded substrates and the possible influence of the 
enteric film on the physical properties as well as dissolution/erosion behavior of 
molded HPC needed to be verified. For this purpose, 1 mm thick disk-shaped 
specimens, also prepared by IM and with the same composition as capsules, 
were used as a simple model for physico-mechanical and release 
characterization studies [Zema et al., 2013b, 2013c]. Preliminary data relevant to 
the wettability of HPC disks were acquired. Glass-slides and molded disks made 
of low-density polyethylene (LDPE) were used for comparison, as these inert 
materials were expected to display little/no interaction when in contact with 
aqueous fluids. The wettability of the different surfaces (i.e. molded HPC, molded 
LDPE and glass) by the coating suspension was investigated by means of contact 
angle analysis. During the test, droplets showed a certain tendency to spread on 
the contact surface over 30 s approximately. Therefore, contact angles were 
determined after 1 and 15 s and the difference between values at the two time 
points was used to estimate the spreading ability of the coating suspension 
(Table 1). 
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Table 1: Contact angles of Eudragit® L 30 D-55 coating suspension with different 
substrates after 1 and 15 s contact-time (s.d. in brackets) and their 
percentage difference (∆ %). 
 
 
Contact time, s 
Contact angle, ° 
(s.d.) 
∆ % 
 
HPC-based molded disk 
1 33.3 (1.26) 
26.4 
15 24.5 (4.43) 
LDPE-based molded disk 
1 57.5 (3.70) 
27.3 
15 41.8 (1.26) 
glass slide 
1 23.7 (1.53) 
25.3 
15 17.7 (0.58) 
 
 
Similar contact angles were observed for HPC-based molded disks and glass 
slides; much higher contact-angle values were obtained for LDPE disks, likely due 
to the hydrophobicity of the material. The spreading ability of the aqueous 
polymeric dispersion, as indicated by the ∆ % values, seemed to be less 
influenced by the characteristics of the surfaces. Based on these results, glass 
slides were selected as reference inert controls for subsequent experiments. 
In order to gain qualitative information about the adhesion of the acrylic film to 
the molded substrates and the surface phenomena arising from HPC interaction 
with aqueous fluids, molded disks and controls were coated with a polymeric 
suspension (equivalent to 10 mg/cm2 of polymer) containing a fluorescent 
marker, namely fluorescein, that could be detected by confocal laser scanning 
microscopy (CLSM). Some disks were also sprayed for a few seconds with an 
aqueous solution of fluorescein alone at the same concentration as in the 
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coating suspension to gain insight into the interaction between HPC and the 
polymeric suspension early in the coating process. The ability of the coated disks 
to withstand acidic media and dissolve in buffer pH 6.8, i.e. their gastroresistance 
performance, was thus investigated. In Table 2, CLSM images of the surface of 
disks and glass slides coated with the marker-containing polymeric suspension or 
maintained 2 h in acidic medium and then transferred in phosphate buffer pH 6.8 
are reported. CLSM images of the coated disks withdrawn from the pH 6.8 
medium after 15-40 min were also compared with those of molded disks sprayed 
with the fluorescein solution and immersed into pH 6.8 buffer for an equal time 
period. In this case, images of the optical cross section of the disks are reported 
(Table 3) where the coating layer thickness or the position of the solvent 
penetration front through the thickness of uncoated disks could be appreciated. 
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Table 2: CLSM images of the surface of molded HPC-based disks and glass slides 
coated with a fluorescein-containing Eudragit® L 30 D-55 suspension 
following immersion in either HCl 0.1N or phosphate buffer pH 6.8 for 
differing time periods.   
 
Medium 
Exposure time 
(min) 
Molded disks Glass slides 
sprayed with fluorescein-containing 
enteric polymer suspension  
- - 
  
HCl 0.1N 10 
  
HCl 0.1N 120 
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Phosphate buffer 
pH 6.8 
(after 2h in HCl 0.1N) 
5 
  
10 
  
20 
  
25 
  
30 
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Table 3: CLSM images of the optical cross section of molded disks coated with a 
fluorescein-containing Eudragit® L 30 D-55 suspension or sprayed with a 
fluorescein solution following immersion in phosphate buffer pH 6.8 for 
differing time periods. 
 
Medium 
Exposure 
time 
(min) 
Molded disks 
sprayed with fluorescein-
containing enteric polymer 
suspension 
sprayed with fluorescein 
solution 
Phosphate 
buffer pH 6.8 
15 
  
25 
  
40 
  
 
In CLSM images the fluorescent marker appears green and helps identify the 
polymeric coating layer. Gradual shading or discontinuous coloring of the green 
surface (Table 2), as well as decrease of the thickness of the green layer in the 
cross section images (Table 3), were related to the dissolution of the coating. 
Both coated disks and glass slides showed a homogeneously colored surface 
before and after being exposed to the acidic medium up to 120 min. On the 
other hand, 25-30 min were necessary for the green color to almost disappear 
from samples once they were transferred into the buffer solution at pH 6.8 
(Table 2). In the optical cross section images of coated disks, a green layer that 
becomes thinner after 25-30 min is evident, which was confirmed to be 
consistent with the time required for the dissolution of the polymeric coating 
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(Table 3). Notably, the coloring of coated disks was generally very similar to that 
of glass controls, which might have suggested an analogous dissolution time 
course for the coating. However, a faded green coloration could still be detected 
after 40 min in pH 6.8 buffer on the molded HPC disks only. Similarly, a green 
shadow was also present at each time point (15-40 min) on disks that were 
sprayed with an aqueous solution of the fluorescent marker. It was thus 
hypothesized that the fluorescein solution could rapidly penetrate through the 
pore network of the glassy matrix, leading to the appearance of the green 
coloration. On the contrary, the diffusion of the marker through the swollen HPC 
molecular chains, both inward and outward, might be relatively slower thus 
making the color leaching out negligible. The faded coloration could therefore 
disappear following dissolution/erosion of the gel layer only. In order to verify 
this hypothesis, the HPC mass loss profile of disks in buffer medium pH 6.8 was 
evaluated (Figure 1): data from coated disks were collected after the dissolution 
of the Eudragit® L film only. 
 
 
Figure 1:  HPC mass loss profiles in phosphate buffer pH 6.8 of molded disks. 
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The mass loss of uncoated disks under the conditions employed was very slow 
(about 45 % within 6 h); in particular, a < 5% decrease in weight was noticed 
during the first hour. The profile of HPC mass loss relevant to coated disks after 
the dissolution of the Eudragit® L film was almost superimposed. Assuming that a 
gel layer could form on the surface of disks on wetting after a few seconds (with 
both the fluorescein solution and the coating suspension) and as no 
dissolution/erosion phenomena had occurred to change the disk surface, the 
faded coloration observed on the disks was confirmed to coincide with the front 
of the initial solvent penetration through the glassy matrix pore network. Mass 
loss profiles also pointed out that the dissolution behavior of molded HPC disks 
was not affected either by the application of an enteric coating (coating process) 
or by the test conditions (2 h in pH 1.2). This was considered a promising result in 
the prospect of achieving coated HPC capsules able to ensure the same pulsatile-
release performance after the dissolution of the enteric coating. 
Considering HPMC capsules, it is known that the glassy-rubbery transition of the 
polymer promoted by the first contact with the coating suspension can bring 
about a sticking tendency of cores, and thus potential issues related to the 
process yield that were also encountered for gelatin cores [McGinity and Felton, 
2008; Thoma and Bechtold, 1992]. As HPC involved the same issue, when 
finalizing the coating process of molded capsules, it will be necessary to identify 
conditions to prevent sticking (i.e. problems related to the tumbling of cores 
within the rotating coating pan or to an incomplete exposure of the shell surface 
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to the sprayed polymeric suspension) and enabling a balance between wetting 
and drying efficiency.  
Finally, as a certain tendency of HPC to water uptake, which could impact the 
mechanical characteristics of shells and stability profile of the filled capsules, was 
already highlighted [Gazzaniga et al., 2011], the potential of the coating layer as 
a barrier for gas diffusion was evaluated by means of Dynamic Vapor Sorption 
(DVS), both at 25 and 40 °C. Evidences that water can act as a plasticizer lowering 
the glass transition temperature of polymers, which leads to a decrease in 
mechanical resistance and adhesive strength, is widely reported in the literature 
[Aulton et al., 1984; Felton and McGinity, 1997; Hancock and Zografi, 1997; 
Okhamafe and York, 1985; Stanley et al., 1981]. Uncoated and coated disks 
maintained under the same storage conditions (24 ± 2 °C/55 ± 5 % RH) showed 
differences in water content (higher for the uncoated) that were also reflected in 
a different duration of the desorption phase (longer for uncoated disks). 
Accordingly, the moisture sorption profiles of uncoated and coated disks turned 
out to be different in terms of both the actual amount of water sorbed and rate 
of sorption. By way of example, results obtained at 25 °C are shown in Figure 2. 
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a)  
 
  
b)  
Figure 2: Moisture sorption profiles of uncoated (a) and coated (b) disks at 25 °C.  
 
Coated samples reached a final water content of 32.41 % vs. 40.70 % of uncoated 
ones. Analogous results were obtained under 40 °C, but in this case a higher rate 
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of water sorption was observed with both types of samples. Lower equilibrium 
moisture contents (≤ 20 %) are reported in the literature for HPC, both untreated 
and processed by hot melt extrusion [Alvarez-Lorenzo et al., 2000; Harwood, 
2003; Prodduturi et al., 2004]. However, the ability of PEG 1500 to promote the 
moisture sorption of plasticized HPC-based blends was already demonstrated for 
IM capsules [Gazzaniga et al., 2011]. The overall results demonstrated the 
potential of the enteric film for limiting water exchange of the molded substrate. 
In the case of coated HPC capsules, this could be advantageous in terms of 
product stability. 
Proof of the ability of the Eudragit® L film to protect molded disks from the 
environment could also be appreciated in the reduction of the warping tendency. 
The coating layer prevented molded items from undergoing a previously 
described deformation, occurring within 72 h from demolding and attributed to 
the presence of the plasticizer in the shell composition [Zema et al, 2013b]. In 
fact, coated disks, stored at the same conditions as uncoated ones, maintained 
their morphology over time (Figure 3). 
 
a)    b)  
 
Figure 3: Photographs of uncoated (a) and coated (b) disks stored at ambient 
conditions after 15 days. 
 
0.5 cm 0.5 cm 
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3.2. Coating process and characteristics of coated capsules 
As the closing system of a capsule may become a critical issue during the coating 
process, both banded and unbanded units of HPC on the one hand, and gelatin 
or HPMC on the other, were considered. During the Eudragit® L 30 D-55 coating 
process, samples with increasing weight gains, i.e. 4, 6, 8, and 10 mg/cm2, were 
withdrawn. The process yield can be calculated from the actual vs. theoretical 
amount of dry polymer applied; in the case of optimal polymer deposition, a 
linear relationship with slope approaching 1 is expected. The rate of polymer 
deposition under the same process conditions was found analogous for the three 
types of cores, and showed the desired slope (Figure 4). Moreover, with the aim 
of reducing the duration of the HPC capsule coating process, the spraying rate 
was doubled still avoiding the sticking of cores and without impacting the 
physico-technological characteristics of the coated units. 
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b)  
 
Figure 4: Profiles of nominal vs actual weight gain (wg) of gelatin (●), HPMC (   ) 
and HPC (▲)capsules, unbanded (a) and banded (b). 
 
In Table 4 the physico-technological characteristics of coated systems are 
compared with those of uncoated IM capsules: by way of example, data relevant 
to unbanded cores as such or coated with increasing amounts of Eudragit® L are 
reported. 
 
Table 4: Characteristics of HPC-based capsules uncoated and coated with 
increasing amounts of Eudragit® L (CV in brackets). 
 
Uncoated 
capsules 
Capsules coated with increasing 
nominal amounts of polymer 
(mg/cm
2
):  
 4 6 8 10 
Weight, mg 
229.2 
(0.26) 
323.6 
(0.64) 
329.4 
(0.47) 
336.2 
(0.63) 
344.3 
(0.47) 
Actual amount of polymer, mg/cm
2 
- 3.58 5.65 7.73 10.16 
Coating thickness, µm - 63.40  88.25  107.20  132.15  
Mechanical resistance, N 
71.02 
(5.02) 
84.56 
(2.99) 
92.23 
(1.09) 
95.54 
(3.06) 
97.01 
(4.62) 
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The actual amount of pure polymer applied onto IM capsules turned out close to 
the theoretical, confirming the ability to maintain an almost constant deposition 
rate even under the more stressful process condition of increased spraying rate. 
Moreover, the increase in the coating thickness appeared nearly linear within the 
range of weight gain considered (data not shown). When applied onto IM 
capsules, the enteric coating demonstrated to improve the mechanical resistance 
of the system. In the presence of a coating film, the maximum force borne by 
capsules before breaking was higher with respect to uncoated ones, but the 
increase in the mechanical resistance was not directly proportional to the 
amount of Eudragit® L applied. The coating film would not only impact on the 
hardness of capsules directly, but also by affecting the relevant humidity content 
[Bley et al., 2009; Cerea et al., 2004]. Indeed, the potential ability of the 
Eudragit® L film to reduce the final water content of HPC-based substrates was 
shown earlier with the molded disks. 
The quality of the enteric coating applied to molded capsules was finally 
investigated by means of optical microscope and SEM analysis. When considering 
capsular cores, the application of the coating film onto the closing system, i.e. 
the overlapping area between the cap and body, may be a critical issue. In Figure 
5 technical drawings of capsules and SEM images of uncoated and coated (10 
mg/cm2) systems are reported: in particular, details of closing systems of both 
banded and unbanded cores are shown. 
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HPC capsules were produced with a locking mechanism based on the mutual 
pressure exerted by the contact areas of matching items so that the body and 
cap components, once assembled, would not entail any junction gap [Zema et 
al., 2013b]. This was confirmed by SEM images of the overlapping areas: in 
particular, the very tight adherence of HPC cap and body items with respect to 
gelatin and HPMC ones was pointed out. The plane external surface of the 
closing area that was devised for HPC capsules in order to ensure a constant shell 
thickness also turned out advantageous to the application of coatings. In fact, no 
discontinuities of the film applied to the overlapping area were observed, 
independent of whether the cores were banded or unbanded, thus suggesting 
that a sealing step could be avoided. Conversely, a continuous coating layer 
covering the closure of gelatin and HPMC capsules was only obtained with band-
sealed cores. These findings were then confirmed by the release performance of 
the coated systems, as described in the subsequent section of the paper. Finally, 
the effective adhesion of the coating to HPC capsules, as demonstrated by a 
smooth and homogeneous surface with a lack of observable cracks or pores, 
could be attributed not only to the improved locking system but also to the 
rough surface of the molded devices, similar to that previously reported with 
HPMC capsule shells [Felton et al., 2002].  
Enteric-coating of pulsatile-release capsules   
prepared by injection molding                                                                      Results -  Chapter 2 
82 
 
 
 
Figure 5: Technical drawings and SEM images of gelatin, HPMC and HPC capsules, 
unbanded and banded, uncoated and coated (10 mg/cm2). 
 
Optical microscope images of the cross section of HPC capsules, uncoated, 
withdrawn from the coating pan after 1 min of processing or coated up to 10 
mg/cm2 are reported in Figure 6.  
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a) b)  
c)  
 
Figure 6: Optical microscope images of the cross section of cleaved capsules 
uncoated (a), withdrawn from the coating pan after 1 min (b) and 
coated with 10 mg/cm2 of polymer (c). 
 
The wall thickness measured from the uncoated capsule image (around 630 µm) 
was in agreement with data previously reported [Zema et al., 2013b]. On the 
other hand, the wall thickness of the sample withdrawn after 1 min of coating 
was increased slightly. This was probably due to a slight swelling of the HPC 
capsule surface promoted by contact with the aqueous Eudragit® suspension, as 
previously observed with the molded disks. Looking at the coated capsules, a 
~130 µm thick homogeneous layer, relevant to the enteric film, can be seen on 
631.95 µm 
131.70 µm 
642.09 µm 
639.09 µm 
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the external side. Such a layer perfectly matches the curved surface of the 
capsular core. Also in this image, the shell thickness is of ~640 µm as after 1 min 
of coating. Indeed, the measured thickness of the enteric coating is in agreement 
with the calculated mean value that is reported in Table 4.  
Finally, the release performance of the coated devices was studied: banded and 
unbanded capsules, coated with increasing amounts of polymer, were evaluated 
and compared with conventional gelatin and HPMC ones. In table 5, t10%, i.e. the 
time to 10 % dissolution/release, and t90-10%, i.e. the time elapsed between 10 % 
and 90 % release, are listed; in the case of HPC capsules, these parameters were 
used as an index of the duration of the lag phase and of the release process, 
respectively. 
 
Table 5: Dissolution/release data of uncoated and coated systems: (a) t10% of 
gelatin and HPMC capsules; (b) t10% and t90-10% of HPC capsules. 
   Gelatin capsules HPMC capsules 
 wg 
(mg/cm
2
) 
t10%, min (CV) t10%, min (CV) 
 Banded Unbanded Banded Unbanded 
Uncoated - 
0.50 
(32.90) 
0.32 
(2.93) 
8.01 
(17.47) 
6.09 
(34.20) 
Coated 
4 
121.46 
(0.01) 
48.37 
(97.83) 
121.32 
(0.51) 
100.42 
(21.62) 
6 
120.98 
(0.54) 
89.96 
(60.30) 
122.05 
(0.79) 
102.70 
(31.45) 
8 
121.50 
(0.00) 
121.35 
(0.11) 
122.91 
(7.07) 
121.66 
(0.07) 
10 
123.25 
(0.45) 
121.60 
(0.57) 
129.51 
(5.62) 
121.91 
(0.40) 
a) 
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  HPC capsules 
 wg 
(mg/cm
2
) 
t10%, min (CV) t90-10%, min (CV) 
 Banded Unbanded Banded Unbanded 
Uncoated - 
44.98 
(11.88) 
36.31 
(2.37) 
8.54 
(12.56) 
10.08 
(8.47) 
Coated 
4 
146.99 
(5.22) 
144.66 
(4.67) 
11.60 
(1.29) 
12.61 
(3.83) 
6 
149.51 
(2.47) 
150.88 
(0.31) 
10.34 
(4.59) 
11.89 
(5.46) 
8 
159.52 
(1.67) 
159.51 
(1.90) 
9.88 
(4.38) 
9.51 
(7.65) 
10 
171.98 
(2.95) 
168.64 
(5.82) 
11.57 
(1.99) 
10.14 
(0.35) 
b) 
 
The good quality of the enteric-coated HPC capsules was confirmed by the 
relevant release behavior. Uncoated IM capsules provided a pulsatile release 
performance characterized by a lag time (t10%), due to the dissolution/erosion of 
the shell, and a pulse time, i.e. the time elapsed between onset and completion 
of release (t90-10%): the obtained t10% and t90-10% values from this study are in 
agreement with previously reported values [Zema et al., 2013b]. The lag time of 
enteric coated capsules was longer with respect to that of uncoated ones, as 
expected, and increased as a function of the amount of polymer applied. In the 
case of the coated systems, in fact, both the ability of the film to withstand acidic 
media and the time needed for the opening of pulsatile delivery capsules would 
contribute to the overall lag time. Although it was not possible to discriminate, 
the lag phase seemed to be consistent with effective gastric resistance (2 h in 
acidic media) and opening time of the uncoated shells, at least for systems with 
10 mg/cm2 coating level. Moreover, no impact of the coating layer on the release 
performance after capsule opening was highlighted: indeed, pulse times of 
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coated systems were analogous to those of uncoated capsules. The tightness of 
the shell closing system was further supported as no differences in drug release 
were observed between banded and unbanded capsules, thus confirming that 
the sealing of IM cores could be avoided. In contrast, in the case of gelatin and 
HPMC capsules, the minimum amount of polymer applied (4 mg/cm2) was 
sufficient to ensure gastric resistance of banded cores only, whereas this amount 
needed to be increased to 8 mg/cm2 with unbanded units. 
 
4. Conclusions 
The feasibility of coating HPC-based molded capsules intended for pulsatile 
release of drugs with Eudragit® L 30 D-55 was evaluated. When enteric coated, 
such capsules would come into contact with aqueous GI fluids only after stomach 
emptying thus being able to target the colonic region through lag phases 
matching the small intestinal transit time of dosage forms (time-dependent 
approach). 
Prototype capsules of 600 µm thickness that were already demonstrated to 
provide, both in vitro and in vivo, a lag phase prior to the onset of release were 
employed. However, in view of the peculiar substrate involved, the application of 
the Eudragit® L film and characterization of coated products were preliminarily 
carried out on molded disks intended for screening purposes. The polymeric 
films generally exhibited consistent behavior independent of whether they were 
applied to the molded disks or to reference glass slides: in both cases, they were 
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able to withstand the acidic medium and dissolve in 25-30 min after switching to 
phosphate buffer.  
Interestingly, the enteric coat showed a potential for improving the physical 
stability of molded products by reducing their moisture sorption and warpage 
tendency as well as increasing the overall mechanical resistance. IM capsules 
were successfully coated with increasing amounts of Eudragit® L leading to 
systems with good technological properties and the desired release 
performance, i.e. a lag time compatible with the maintenance of gastric 
resistance and same pulsatile profile in the pH 6.8 medium as the uncoated 
devices. The capsule closing system turned out effective with no need for a 
sealing to be applied before the coating process and suitable for the 
achievement of a homogeneously layered coating of constant thickness. 
The obtained results highlighted the potential of Chronocap™ capsules for being 
exploited as core units in the development of colon delivery systems based on a 
time-dependent approach. 
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1. Objective 
Within a general research project aimed at the development of a capsule-shaped 
drug delivery system (DDS) prepared by injection molding (IM) and intended for 
pulsatile release and/or time-dependent colonic delivery of drugs (Chronocap™ 
platform), the modulation of the typical lag phase of such a device was in-depth 
investigated. The possibility of preparing containers for drug formulations, 
purposely designed for achieving pre-defined lag times prior to release, would be 
advantageous in chronotherapy. Moreover, the time-dependent approach to 
target the colonic region is based on the administration of gastroresistant 
pulsatile delivery systems able to impart a lag phase, starting after stomach 
emptying, of a defined duration, i.e. 3 h ± 1 standard error, consistent with the 
small intestinal transit time of dosage forms.  
A correlation between the duration of the lag phase and the thickness of IM 
capsule shells was previously demonstrated by means of a prototype mold that 
allowed capsules with 300, 600 and 900 µm thick walls [Gazzaniga A. et al., 2011] 
to be manufactured. In the present chapter, formulation strategies possibly 
suitable for the modulation of the opening time of the Chronocap™ shells were 
therefore evaluated. In particular, an extension of the lag phase was pursued. A 
first approach was based on slowing down the hydration/swelling phase of HPC, 
which is the basic component of the capsule shells. As a consequence, the break-
up of systems after the dissolution/erosion of the shell is expected to occur later 
and the liberation of capsule contents to be further delayed. For this purpose  
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the use of alternative swellable polymers and/or swelling adjuvants (HPC grades 
with higher molecular weight and disintegrants), as well as the addition of 
insoluble and inert adjuvants (ethylcellulose and talc) were evaluated. 
 
2. Materials and methods 
2.1. Materials 
Hydroxypropyl cellulose (HPC): Klucel® LF and GF, Eigenmann & Veronelli, I; 
sodium starch glycolate, Explotab CLV®, JRS Pharma, US; ethyl cellulose: Ethocel® 
100std, Colorcon, US; talc, Carlo Erba Reagenti, I; polyethylene glycol (PEG) 1500, 
Clariant Masterbatches, I; acetaminophen (AAP) fine powder, Atabay, TR. 
 
2.2. Methods 
2.2.1. IM process 
A mixture of formulation components, previously dried in a ventilated oven for 
24 h at 40 °C, and 10 % by weight of PEG 1500 was prepared in Turbula® (Type 
T2C; WAB, CH) and then transferred into a bench-top micromolding machine 
(BabyPlast 6/10P; Cronoplast S.L., ES; Rambaldi S.r.l., I). In Table R3.1 the 
composition (%, by weight) of the polymeric formulations processed by IM is 
reported. 
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Table R3.1: Codes and composition of molded formulations. 
Code Formulation composition (% by weight) 
KL  Klucel® LF (90%) + PEG 1500 (10%)  
KLKG 7/3  (Klucel® LF 70% + Klucel® GF 30%) (90%) + PEG 1500 (10%)  
KLKG 5/5  (Klucel® LF 50% + Klucel® GF 50%) (90%) + PEG 1500 (10%)  
KG  Klucel® GF (90%)  + PEG 1500 (10%)  
KLEX5  (Klucel® LF + PEG 1500 (10%)) (95%) + Explotab CLV® (5%)  
KLEX10  (Klucel® LF + PEG 1500 (10%)) (90%) + Explotab CLV® (10%)  
KLEX20  (Klucel® LF + PEG 1500 (10%)) (80%) + Explotab CLV® (20%) 
KLEX30  (Klucel® LF + PEG 1500 (10%)) (70%) + Ethocel® 100std (30%)  
KLEC20  (Klucel® LF + PEG 1500 (10%)) (80%) + Ethocel® 100std (20%)  
KLTA20  (Klucel® LF + PEG 1500 (10%)) (80%) + Talc (20%)  
 
The behavior of polymeric formulations upon heating or IM was evaluated as 
follows:  
Hot-plate experiment: samples of 2-3 g of the Klucel® LF as such or in admixture 
with the selected excipients, were placed in an aluminum pan on a hot plate. 
Samples, under continuous manually stirring, were gradually heated from 30 to 
200 °C in few minutes and the temperature was checked with a laser 
thermometer. Changes of color, aspect and mechanical characteristics of the 
materials upon heating were observed. 
Air shot test: 50 g of  Klucel® LF as such or in admixture with the selected 
excipients, loaded into the molding press through the hopper, were expelled 
from the injecting unit as operating a purge under different operating 
temperatures [Rosato D.V. et al., 2000]. Expelled samples were checked for 
overall aspect, color and mechanical characteristics immediately after ejection 
and when solidified. 
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Some of the polymeric formulation were processed by hot-melt extrusion in a 
microcompounder (Minilab II, HAAKE Rheomex CTW5, Thermo Scientific, D) 
equipped with conical twin screws (diameter 5/14, length 109.5 mm) which can 
either co- or counter-rotate. Operating temperatures were selected in the range 
of 130-160 °C; the rotation speed of the screws was set at 15 rpm. The extruded 
product was milled before being loaded in the IM press. 
IM items were prepared by means of either a capsular mold with two 
interchangeable inserts for the manufacturing of matching caps and bodies of 
600 µm nominal thickness, or a disk-shaped mold (diameter: 30 mm; height: 1 
mm) provided with a central gate. Process conditions were varied within 
different ranges of values depending on the item produced (disk or capsule) 
(Table R3.2). 
 
Table R3.2 : IM process parameters. 
 disk capsule 
 
  
compression zone temperature; °C 140-160 100-130 
metering zone temperature; °C 150-160 130-140 
nozzle temperature; °C 160-170 140-150 
hot runner temperature; °C - 160-170 
charge; mm 15-16 4 
1
st 
injection 
pressure; bar 50-60 30-60 
time; s 0.6 0.4 
rate; % 50-60 30-60 
2
nd 
injection 
pressure; bar 10-50 10-50 
time; s 2 0.3 
rate; % 10-40 10-50 
cooling temperature; °C 15 15 
cooling time; s 2.5 2.5-3 
closing pressure; bar 80 120 
opening rate; % 90 90 
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2.2.2. Characterization of molded items 
IM disks and capsules were checked for weight by an analytical balance 
(Sartorius BP211D, Sartorius AG, D; n=10) and for thickness by a digital 
micrometer (Mitutoyo IT-012U, Mitutoyo, J; n=10) immediately after ejection 
and after 24, 48, 72 h storage at ambient conditions (24 ± 2 °C/55 ± 5% relative 
humidity, RH). 
Digital photographs of molded capsules were acquired by a Nikon D70 camera 
(Nikon, J). 
 
Dissolution/erosion properties of molded disks upon contact with aqueous fluids 
were assessed by a mass loss test performed in the pharmacopoeial apparatus 2 
(Dissolution System 2100B, Distek, US) at 100 rpm. Each sample, weighed (pi) 
and inserted in a closed system prepared from a polyethylene net (2 mm mesh), 
was then weighed again in order to determine the tare (t) and placed in a vessel 
containing 600 mL water kept a 37 °C. Samples (n=3) were withdrawn every 30 
min, then placed in a ventilated oven at 40 °C for 24 h and weighed (pf). 
Percentage of residual mass was calculated according to Eq. (1): 
 
                                            
            
  
                                                 Eq. (1)                 
 
Both the release performance and the opening behavior under unstirred 
conditions of capsular systems were evaluated.  
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The in vitro release test of capsules (n=6) containing 150 mg of AAP powder was 
performed in a six-position USP 34 disintegration apparatus [Gazzaniga A. et al., 
1995]. Each capsule was inserted in one of the six available tubes of the basket-
rack assembly, which moved at 31 cycles/min rate in separate vessels; each of 
these contained 800 mL deionized water kept at 37 ± 0.5 °C. Fluid samples were 
withdrawn at fixed time points and assayed spectrophotometrically at 248 nm. 
10 and 90 % drug released were calculated for each sample from the relevant 
release pattern (n = 6); 10 % value (t10%) was defined as lag time (i.e. the time 
required for the opening of the system), while the time elapsed between 10 % 
and 90 % release (t90%–10%) was defined as pulse time (i.e. the time required for 
completion of the release process). 
The morphological changes of filled capsules exposed to deionized water at 
ambient temperature under unstirred conditions were evaluated over 6 h. Digital 
photographs were taken every 5 min. 
 
3. Results and discussion 
HPC is commercially available in several types (e.g. Klucel® products) based on 
the molecular weight (average 50000-1250000 Da) and the grade of substitution 
of hydroxyl groups. Such characteristics may influence the behavior of polymeric 
chains when in contact with aqueous fluids, i.e. the rate and extent of 
hydration/swelling, and the viscosity of the polymer aqueous solutions. 
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When employed as hydrophilic swellable barriers in the form of capsule shells, 
different HPC grades may lead to a diverse opening of the device and, thus, to a 
range of modified release profiles of the conveyed drug. With respect to the 
processability of HPC by IM, neither the glassy-rubbery transition (Tg) of the 
polymer nor the relevant hot-melt extrusion temperatures seem to be 
dependent on the molecular weight [Trey S.M., et al., 2007]. Hence, in order to 
improve the versatility of the Chronocap™ platform by increasing the lag phase 
prior to release, the feasibility of capsular containers prepared from different 
Klucel® grades or blends was considered. For this study, the previously 
established formulation based on Klucel® LF (KL: Klucel® LF + 10% by weight PEG 
1500) and the molded capsules obtained were considered as the reference for 
the evaluation of both the processability of the new materials and the release 
performance of resulting devices. The alternative to Klucel® LF (MWLF 95000) 
taken into account was Klucel® GF, which has a higher molecular weight (MWGF 
370000). The possibility of exploiting the same plasticizer was preliminarily 
explored: hot-plate experiments and air shot tests were performed on polymeric 
blends with increasing amount of PEG 1500. By heating the material under 
continuous manual mixing, while gradually increasing the temperature up to 
200°C, not only the range of working temperatures can be defined, but also 
possible issues of the heating process may be highlighted, such as a rapid 
transition of the molten mass to a liquid state, a lack of homogeneity or the 
occurrence of degradation phenomena at each stage. Moreover, the aspect and 
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mechanical characteristics of products after cooling can be checked. On the 
other hand, by expelling the material loaded in the IM press from the injection 
unit, the characteristics of the product can be related to the working parameters, 
which may be helpful for gathering information about the suitability of the 
material for IM processes. Also in this case, the material can be evaluated not 
only as soon as ejected from the nozzle, but also after its cooling/hardening. 
Such preliminary studies confirmed the processability of Klucel® grade GF by 
employing the same type and amount of plasticizer already used for the LF one 
(KG: Klucel® GF + 10 % w/w PEG 1500).  
Capsules could be prepared from formulations KL and KG and their blends (KLKG 
7/3: 70% KL + 30% KG and KLKG 5/5: 50% of both KL and KG). However, failures 
in the automatic ejection of molded half shells and minor imperfections of the 
surface were noticed in some cases. 
When dealing with polymeric blends, the poor mixing ability of the IM press used 
could turn out critical. In this respect, some attempts were made to improve the 
homogeneity of distribution by pre-extruding blends of raw materials. For this 
purpose, a lab-scale twin-screw extruder (microcompounder) equipped with 
conical co-rotating and counter-rotating screws was used. The extrusion 
temperature was defined within the range of temperatures already involved in 
the IM process: 160 °C was identified as the temperature leading to the 
complete glassy/rubbery transition of raw materials (no evidence of particles in 
the extrudate) and to the lowest value of torque (i.e. the strain/stress of the 
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rotating screw measured in N·m) registered. For the manufacturing of capsules 
based on pre-extruded formulations, minor changes of process parameters were 
needed with respect to those not treated. However, molded units were obtained 
with no imperfections and major issues related to the automatic ejection of 
molded products could be overcome. 
The characteristics of weight and thickness of capsules based on Klucel® LF, GF 
and their blends are reported in Table R3.1: product codes followed by “-e” 
refers to pre-extruded formulations. 
 
Table R3.1: Weight and thickness of capsules based on Klucel® LF, GF and their 
blends. 
 
formulation 
 
weight (mg) thickness (µm) 
mean CV mean CV 
KL 221 0.83 609 1.35 
KL co-e 228 0.05 613 1.02 
KL counter-e 228 0.04 616 2.38 
KLKG 7/3 226 1.59 614 1.78 
KLKG 5/5 225 0.68 614 1.86 
KLKG 5/5 co-e 226 0.23 611 1.59 
KLKG 5/5 counter-e 227 0.27 616 2.60 
KG 219 0.81 614 0.81 
 
The characteristics of capsules made of blends of Klucel® GF turned out not to be 
significantly different (p < 0.05) from those based on the LF formulation. 
Moreover, even the pre-extrusion treatment of raw materials demonstrated to 
impact on the weight and thickness of molded shells. 
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The in vitro release performance of capsules filled with a powder drug tracer was 
then assessed. Two parameters were used to describe release profiles (Table 
R3.2): the lag time (calculated as the time to 10% release, t10%) and the pulse 
time (t90-10%), i.e. the time elapsed between onset (t10%) and completion (t90%) of 
the release. 
 
Table R3.2: Release parameters of capsules based on Klucel® LF, GF and their 
blends. 
 
Formulation 
 
lag time (min) pulse time (min) 
mean CV Mean CV 
KL 25.22 10.47 6.24 16.05 
KL co-e 27.00 5.62 5.13 6.93 
KL counter-e 28.37 14.36 7.36 9.57 
KLKG 7/3 34.13 6.54 5.86 14.50 
KLKG 5/5 38.27 3.46 6.93 35.93 
KLKG 5/5 co-e 38.08 8.82 5.62 14.21 
KLKG 5/5 counter-e 42.25 5.28 8.54 14.29 
KG n.d. n.d. n.d. n.d. 
 
The lag time of capsules made of blends of formulations KL and KG turned out 
10-15 minutes longer (p < 0.05) with respect to the KL reference. The application 
of an extrusion pre-treatment generally demonstrated not to affect the 
performance of devices, neither in the case of the KL formulation as such nor in 
that of its blends with the KG. Only with the KLKG 5/5 formulation pre-treated by 
the counter-rotating twin-screw extruder, the device obtained showed a lag time 
few minutes longer (p < 0.05) than that of the same formulation not previously 
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extruded or pre-treated by co-rotating screws. The presence of different 
amounts of Klucel® GF in the shell formulation, 30 or 50 %, seemed to not affect 
the lag time of release. With respect to the time for the complete opening of the 
systems (pulse time) containing Klucel® LF, it turned out independent of the 
composition and manufacturing procedure of capsule shells and always < 9 min. 
On the contrary, the release performance of KG systems was definitely different 
from that of all the other and was characterized by a high variability (Figure 
R3.1). Lag times of hours and slow release profiles were observed, which could 
indicate a problematic opening mechanism: the drug tracer, in fact, had 
generally started to diffuse out through the gelled structure of the shell wall 
before it broke. Moreover, few capsules didn’t even start to release their 
contents by 6 hours (duration of the test). Release parameters for capsules made 
of the GL formulation could not be determined.  
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Figure R3.1: In vitro release profiles of capsules based on Klucel® LF, GF and their 
blends. 
 
Based on the results obtained, it was hypothesized that the contribution of 
Klucel® GF to the lag time duration of capsules made of blends of formulations KL 
and KG was that of slowing down the rate of hydration and dissolution/erosion 
of the external polymeric layers that leads to the formation of first aperture in 
the shell. Afterwards, the overall resistance of the remaining gel barrier seems 
not to be affected as similar pulse time were calculated for all the devices based 
on polymeric blends. However, such a result could be attributed to the 
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hydrodynamic conditions of the test promoting the dissolution/erosion rate of 
the swollen barrier. 
In order to confirm these hypothesis and evaluate the influence of the 
hydrodynamic conditions, release tests were carried out under unstirred 
conditions at ambient temperature. Photographs of capsules of the formulation 
KL, KG and their 1/1 mixture representing crucial steps of the release 
performance are reported in Figure R3.2: in particular, the first bubble coming 
out from the initial crack of the capsule shell (image framed in red) and the 
complete opening of the device that leads to the liberation of the powder tracer 
contained (image framed in blue) are depicted. 
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Figure R3.2: Photographs of capsules of Klucel® LF, GF and their 1/1 blend 
immersed in water under unstirred conditions at different time 
points. 
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The LF reference capsule properly underwent hydration with the formation of a 
gel layer that gradually dissolved/eroded until the formation of a first tear; the 
presence of the rupture was evidenced by the leakage of an air bubble that 
occurred after about 50 min of contact with the aqueous fluid. The complete loss 
of integrity of the capsule shell required 85 min more. As expected, the timing of 
capsule opening under unstirred conditions turned out to be noticeably longer 
with respect to both the lag phase and pulse time obtained under the release 
test conditions. Accordingly, the KG shell remained intact over 6 hours; at the 
end of this period, only a thin gel layer was present around the device. The 
capsule composed of the KL and KG formulation blend showed a behavior more 
similar to that of the KL device, but with longer latency before breakage. 
However, even the time to complete the opening of the device turned out 
longer, thus confirming that the resistance of the gel barrier after the formation 
of the first crack is largely affected by the unstirred conditions. 
The objective of improving the duration of the Chronocap™ lag phase by 
introducing a higher viscosity grade HPC in the reference formulation based on 
Klucel® LF was not completely fulfilled. This could be partially attributed to 
difficulties in promoting the intimate contact or the interpenetration of 
polymeric chains during the hot processing. In fact, capsules prepared from 
polymeric blends showed a behavior much more similar to that of one of the 
components (Klucel® LF), even if a ~40% increase of lag time was achieved. 
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However, a further moderate increase of capsule lag time was only obtained 
when the formulation was counter-extruded before being processed by IM.  
Other polymeric materials that could be introduced in the LF formulation of 
capsule shells in order to increase the lag phase were identified. Based on the 
previous experience with Klucel® GF, the most likely mechanism to be exploited 
should be that of hindering the hydration of HPC and its early transition to the 
rubbery state. Accordingly, two different types of excipients, having opposite 
properties upon contact with water, but expected to lead to the same outcome 
in extending the lag time of capsules, were considered: swellable polymers, 
which are intended to partially remove water by absorbing it (competitors), and 
insoluble/inert adjuvants, simply unable to draw water to the system. From the 
former category, L-HPC and sodium starch glycolate (Explotab® CLV) were 
selected. L-HPC is a low-substituted HPC, having about 15 times less 
hydroxypropyl groups than Klucel® LF (molar substitution L-HPC = 0.2 vs molar 
substitution Klucel® LF = 3). Moreover, while HPC is soluble in water, L-HPC is 
insoluble, although it strongly retains water molecules and swells [L-HPC 
ShinEtsu, technical data. 2011; Kibbe A.H, 2000]; on the basis of this 
characteristic, it is recommended as a disintegrant for the preparation of solid 
oral dosage forms. Also the second material considered, Explotab® CLV, is a 
widely employed and one of the most efficient disintegrants. On the other side, 
with respect to insoluble/inert excipients, some preliminary results were 
obtained with talc and ethylcellulose. 
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As far as the processability of swellable polymers is concerned, since little 
information about their characteristics upon heating is reported in the literature, 
both L-HPC and Explotab® CLV were tested on hot-plate: they didn’t undergo 
melting phenomena typical of thermoplastic materials upon glassy-rubbery 
transition, but showed signs of degradation around 200-250 °C, temperatures 
remarkably higher than those involved in the molding of Klucel® LF-based 
capsules. As no modifications could be observed at the operating temperatures, 
the selected disintegrants were expected to remain suspended in the HPC 
molten mass. For this reason, the processability by the IM press of the KL 
formulation containing L-HPC or Explotab® CLV was evaluated and disk-shaped 
screening items were prepared. In particular, formulations containing 10 and 30 
% by weight of the disintegrant (KLLH10 and KLLH30 with L-HPC; KLEX10 and 
KLEX30 with Explotab® CLV, respectively) were considered. While KL disks turned 
out clear after demolding, those based on the polymeric blends with powder 
disintegrants were opaque with white particles visible, more frequent in disks 
containing 30 % by weight of the excipient. 
All the disks were characterized in terms of thickness immediately after 
demolding and over time (up to 1 month) (Figure R3.3). 
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Figure R3.3: Variation over time of the thickness of molded disks based on 
Klucel® LF as such and blended with 10 and 30 % by weight of 
Explotab® CLV or L-HPC. 
 
As already observed while working with HPC [Zema L. et al., 2013], the thickness 
of KL disks turned out higher (around 10 %) with respect to nominal 1000 µm. 
This tendency, mainly related to inner tensions formed during the 
rearrangement of the polymeric chains inside the mold [Fisher J.M., 2003], 
seemed to be limited by the presence of suspended particles of the 
disintegrants: by way of example, the thickness of KLEX30 disks after demolding 
was around 2.5 % greater than the nominal. Moreover, thickness values tended 
to increase over time, at least for 48 hours. 
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In order to gain preliminary information about the dissolution/erosion 
performance of the molded items based on polymeric blends containing 
disintegrants, the mass loss trend over time was studied; tests were carried out 
on disks stored for a week (Figure R3.4). 
a)  
b)  
 
Figure R3.4: Dissolution/erosion profiles of molded disks containing 10 % (a) or 
30 % by weight (b) of disintegrants. 
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The 10% of an additional swelling agent seemed not to influence the erosion rate 
of molded disks except for Explotab® CLV that showed a slight tendency to slow it 
down during the first h of the test (Figure R3.4). The same trend was noticed 
with disks containing the highest amount (30% by weight) of L-HPC. This 
behavior was attributed to the different ability of disintegrants to compete 
against Klucel® LF for water. Accordingly, when increasing the amount of 
Explotab® CLV in the formulation, the effect of inhibiting the hydration rate of 
HPC was counterbalanced by the swelling of the disintegrant polymeric chains, 
and thus the result was that of promoting to some extent the erosion of molded 
disks. 
Capsular containers were prepared starting from formulations containing from 5 
to 30 % by weight of Explotab® CLV (KLEX5, KLEX10, KLEX20 and KLEX30) or 10 
and 30 % by weight of L-HPC (Table R3.4).  
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Table R3.4: Weight and thickness of capsules based on Klucel® LF and its blends 
with Explotab® CLV or L-HPC. 
 
formulation 
weight (mg) thickness (µm) 
mean CV mean CV 
KL 211.00 0.83 609 1.35 
KLEX5 233.08 0.13 621 1.61 
KLEX10 233.55 0.14 626 2.70 
KLEX20 239.29 0.09 633 1.89 
KLEX30 248.55 0.71 629 2.33 
KLLH10 243.08 0.85 631 1.45 
KLLH30 245.45 0.47 636 1.72 
 
When preparing capsules with blend formulations, IM parameters needed to be 
modified with respect to reference KL capsules, especially in terms of injection 
pressure and rate. This was probably the reason why the weight and thickness of 
molded shells turned out generally higher. 
As far as the release performance of capsules is concerned (Table R3.5 and 
Figure R3.5), the results obtained were in good agreement with premises: 
capsules with the lower amounts of disintegrants in the shell formulation 
showed an increase up to 20 min (~80%) of the lag time with respect to the 
reference. This increase was proportional to the disintegrant content. Only in the 
case of devices containing 20 and 30 % of Explotab® CLV, an opposite tendency 
towards a reduction of the lag time was observed, that was attributed to the 
early erosion of shell walls promoted by the disintegrant swelling. With respect 
to devices containing 30 % of L-HPC in the shell formulation, although their mean 
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lag phase was the longest achieved from the devices tested, it was however 
characterized by the higher variability clearly evidenced in Figure R3.5. As this 
could be attributed to a not homogeneous distribution of the disintegrant in the 
injected molten mass, a preliminary evaluation of the effect of pre-extruding the 
polymeric formulation according to procedures already tested with Klucel® 
LF/Klucel® GF blends was carried out. Unfortunately, the release behavior of 
capsules prepared from co-extruded or counter-extruded formulations turned 
out not significantly different from the untreated ones.  
All capsules, irrespective of the presence of a disintegrant in the formulation 
composition, demonstrated the desired pulsatile-release profile with a pulse 
time not different from that of the reference.  
 
Table R3.5: Release parameters of capsules based on Klucel® LF and its blends 
with Explotab® CLV or L-HPC. 
 
formulation 
 
lag time (min) pulse time (min) 
mean CV mean CV 
KL 25.22 10.47 6.24 16.05 
KLEX5 37.50 6.46 6.15 18.74 
KLEX10 46.70 8.46 6.34 10.05 
KLEX20 36.96 6.04 6.02 13.09 
KLEX30 36.49 6.04 5.79 7.60 
KLLH10 35.81 6.78 8.24 10.76 
KLLH30 49.50 15.99 6.10 11.07 
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Figure R3.5: In vitro release profiles of capsules based on Klucel® LF and its 
blends with Explotab® CLV (5, 10, 20 and 30 %) or L-HPC (10 and 
30%). 
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Afterwards, the research work went through a further investigation of the 
opening behavior of HPC capsules containing disintegrants in the shell walls by 
testing them under unstirred conditions. Devices with 10 or 30 % of Explotab® 
CLV, the release performance of which had suggested different hypotheses in 
regard to the opening mechanism, were considered and compared with 
reference capsules (Figure R3.6). 
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Figure R3.6: Photographs of capsules based on Klucel® LF and its blends with 5 or 
10 % of Explotab® CLV immersed in water under unstirred 
conditions at different time points. 
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The overall results obtained were useful to confirm the hypothesized working 
mechanism of disintegrants when present in the formulation of HPC capsules. 
The ability of the disintegrant to delay the appearance of the first break in the 
shell wall was evidenced: over 1 hour in the case of the capsule containing 10 % 
of Explotab® CLV. Indeed, the opening position of such a tear was different with 
respect to the reference product. Moreover, the highest amount of Explotab® 
CLV was confirmed to be sufficient to bring about a disintegrating force 
contributing to the complete break-up of the device. In fact, the KLEX30 capsule 
broke up leading to the complete release of its content about 2 hours before the 
one with only 10 % of disintegrant (KLEX10). 
With the same purpose of slowing down the hydration rate of the HPC barrier of 
capsules, the addition to the formulation of insoluble materials such as talc and 
ethyl cellulose was preliminarily evaluated; blends of Klucel® LF and 20 % by 
weight of the excipient (KLTA20 and KLEC20, respectively) were therefore 
considered. Talc was expected to remain dispersed in the molten polymeric mass 
and carried through the IM phases in the same way as previously used insoluble 
materials (disintegrants). Accordingly, opaque molded items were obtained with 
some particles visible on the surface. As far as the EC is concerned, it is a 
thermoplastic polymer but with a transition temperature around 130 °C, higher 
with respect to the operating temperatures needed for HPC capsules. However, 
when dispersed in the KL formulation, in the presence of a plasticizer, it was 
probably able to melt at lower temperatures giving rise to clear and 
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homogeneous molded items. With both the formulations the IM process was 
carried out with no need for changes of parameters, except for a 10 °C increase 
of the operating temperature. 
Weight and thickness of capsules are reported in Table R3.6 while release 
parameters and profiles are shown in Table R3.7 and Figure R3.7, respectively. 
 
Table R3.6: Weight and thickness of capsules based on Klucel® LF and its blends 
with 20 % of talc or EC. 
 
formulation weight (mg) thickness (µm) 
 Mean CV mean CV 
KL 211.00 0.83 609 1.35 
KLTA20 256.69 0.54 630 3.78 
KLEC20 225.97 0.44 626 1.40 
 
Table R3.7: Release parameters of capsules based on Klucel® LF and its blends 
with 20 % of talc or EC. 
 
formulation 
lag time (min) pulse time (min) 
Mean CV mean CV 
KL 25.22 10.47 6.24 16.05 
KLTA20 33.05 10.40 5.13 9.70 
KLEC20 46.81 3.15 6.54 16.67 
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Figure R3.7: In vitro release profiles of capsules based on Klucel® LF and its blends 
with 20 % of talc (KLTA20) or EC (KLEC20).  
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whether modifications in the qualitative or quantitative composition may lead to 
different lag phase durations or release mechanisms.  
 
The overall results obtained from the addition of both swellable/disintegrant and 
insoluble adjuvants to the formulation of the HPC-molded shell indicated that 
the decrease of the hydration rate of its main component, Klucel® LF, could be a 
promising strategy for improving the duration of the lag time of the device. 
However, some limitations, likely related to the poor ability of the IM press 
employed to apply mixing shear forces in the plasticating unit, were highlighted. 
The possibility of overcoming the problem by hot-compounding of polymeric 
formulations in a twin-screw extruder before their IM processing was evaluated: 
it was demonstrated a valuable approach to improve the distribution of solid 
particles within a molten polymeric mass and gave proof of being a pursuable 
strategy for promoting a more intimate contact/interaction between different 
types of polymeric chains. The possibility of achieving different performances 
with the new polymeric compounds eventually obtained still needs to be 
confirmed. 
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The research project was focused on the development of a pulsatile capsular-
shaped drug delivery system (DDS) named Chronocap™. It consists of a capsule 
shell, made of an hydrophylic swellable/erodible polymer (hydroxypropyl 
cellulose, HPC) and prepared by injection molding (IM), intended to be filled with 
different types of drug preparations and to delay their liberation after oral 
administration. The feasibility by IM of capsules based on Klucel® LF was already 
assessed by means of a prototype mold allowing shells of different thickness 
(300, 600 and 900 µm) to be obtained. Such devices were demonstrated able to 
convey drug preparations giving rise to the expected pulsatile release 
performance, confirmed by in vivo data. The lag phase was attributed to the slow 
interaction of HPC with aqueous fluids, leading to the formation of a gel-barrier 
the break-up of which takes place as a consequence of dissolution/erosion 
phenomena; accordingly, such lag phase turned out to increase as a function of 
the shell wall thickness. The PhD project was undertaken aiming at improving the 
robustness and versatility of the Chronocap™ device as well as enhancing the 
industrial scalability of its manufacturing process. For this purpose, two different 
tasks were pointed out: the improvement of the manufacturing process and of 
the technological characteristics of capsules on the one side, and the upgrade of 
applications of the device on the other. In this respect, the modulation of the lag 
phase of the capsular device and its possible exploitation in the design of a colon 
DDS were approached.  
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A new mold was designed based on the thermal, rheological and mechanical 
characteristics of the Klucel® LF formulation. It enabled the manufacturing of 
capsules improved in terms of reproducibility of the wall thickness and relevant 
consistency with the nominal value, efficiency of the body-cap joint mechanism 
and reliability of in vitro performance. Moreover, the production rate and extent 
of automation of the process were increased [Results – Chapter 1]. 
The possibility of exploiting these capsules for the development of colon delivery 
systems based on a time-dependent approach was initially faced by evaluating 
the Chronocap™ device as the substrate for film-coating with Eudragit® L. 
Screening disks were preliminary prepared by IM and employed for studying the 
interaction of the polymeric coating with the molded surface and the 
gastroresistant performance of the obtained product. Chronocap™ capsules 
could be successfully coated with increasing amounts of the enteric soluble 
polymer. Coated systems showed good technological properties and, at least 
those with the thickest Eudragit® layer, maintained their integrity for 2 h in acidic 
media and released their contents in pH 6.8 buffer after a lag time comparable 
with that of uncoated devices [Results - Chapter 2].  
Finally, the lengthening of the lag phase of molded capsules through formulation 
changes of the composition of the walls was successfully approached. The 
hydration rate of Klucel® LF was reduced by adding swellable and/or insoluble 
materials (e.g. Klucel® GF, L-HPC, Explotab® CLV EC and talc) to the formulation 
of the shell walls. As a consequence, the formation of the first break in capsule 
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walls by dissolution/erosion of the gel barrier was delayed. Pulsatile release 
profiles with longer lag times were obtained from the new systems based on 
polymeric blends. On the contrary, the time required for the complete opening 
of capsules remained < 8 min as for the reference Klucel® LF system. Results 
obtained by pre-extruding some of the polymeric blends prior to IM processing 
showed promising perspectives towards the achievement of longer lag phases 
[Results - Chapter 3]. 
The overall results obtained may lead to the manufacturing of pulsatile and colon 
specific drug delivery prototypes for in vivo testing. 
 
 
